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Devising a Scalable Synthesis to Probe 
the G-Protein Cell Receptor Signaling Pathway 
 
By 
Matthew Robert Medcalf 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2019 
Professor Kevin D. Moeller, Chair 
 
The G-protein coupled cell receptor signaling pathway is amongst the largest and most 
diverse class of cell-surface receptors in the body. Nearly 800 different genes encode for these 
cell membrane receptors which are responsible for mediating a variety of hormones, 
neurotransmitters, and sensory stimuli through the activation of intracellular G proteins. To date, 
roughly 34% of pharmaceuticals on the market target GPCR’s, but despite this fact, there are still 
many difficulties associated with targeting this family of receptors. The vast number of GPCR’s, 
disease states resulting from a dysregulation of multiple GPCR signaling pathways, and 
difficulties crystalizing and purifying the receptor—G-protein complex all pose significant 
challenges for targeting GPCR’s. Due to these challenges, in recent years there has been a 
growing interest in targeting the intracellular G protein as an alternative to the extracellular 
GPCR. For example, two known natural products YM-254890 and FR-900359, isolated from 
Chromobacterium sp. QS3666 and Ardisia Crenata respectively, potently and selectively inhibit 
signaling by Gq/11-class G-protein α subunits by trapping them in their inactive GDP-bound 
states. As part of an effort to better understand how these natural products operate and to develop 
xii 
 
chemical probes for the Gq signaling pathway we have developed a scalable solution phase 
synthesis of simplified analogs of YM/FR that retain important regions responsible for binding to 
Gαq. 
Through the use of this convergent synthesis with a longest linear sequence of eight steps 
with an overall yield of 11.6%.  We have successfully synthesized multiple analogs used to 
probe the G-protein cell receptor signaling pathway. While the analogs synthesized to date are 
not as potent as YM or FR, they do selectively bind to Gαq. With these results in place, we are 
now probing the factors that are responsible for binding and potency of the analogs for Gq, along 
with factors that determine the selectivity of the molecules for Gαq.  
To this end, we have developed a new convergent synthesis, applying the lessons learned 
from our second-generation synthesis, that returns functionality found in the natural products. 
We believe the instillation of the “bottom bridge”, a dimer of an N-Me-O-Me-Thr and N-Ac-Thr, 
will provide conformational constraint and return activity lost in the first generation of analogs. 
Once more active analogs have been found, these molecules will be used as probes for 
understanding the biological function of the Gq signaling pathway and as potential lead 




Chapter One: Introduction and Background 
1.1 G Protein Cell Receptor Signaling Pathway 
The G-protein cell receptor (GPCR) signaling pathway is the largest membrane protein 
family with nearly 800 receptors that regulate a wide variety of cellular or physiological 
processes, and a wide variety of disease states. This is reflected in the sheer number of 
pharmaceuticals that target the GPCR, accounting for over a third of the drugs currently 
available on the market.1,2 Every day, numerous neurotransmitters, chemokines, local mediators, 
and sensory stimuli exert their effects on a cell by binding to heptahelical membrane receptors 
coupled to heterotrimeric G proteins.1,3,4 
 
Figure 1.1 – G Protein Cell Signaling Pathway 
Image from: Rensing, D. T. (May 27, 2016). Synthesis of Simplified YM-254890 Analogs, Washington 







In a healthy cell, the GPCR signaling cascade is represented in Figure 1.1. First, a ligand 
binds to a cell surface receptor (step B), promoting exchange of guanosine diphosphate (GDP) 
for guanosine triphosphate (GTP) on the Gα-subunit of the intracellular heterotrimeric G protein 
(Step C). The GTP bound Gα subunit then disassociates from the Gβγ dimer (step D). These 
subunits can then turn on a variety of downfield effectors. Upon completion of the cell signal, 
GTP is cleaved to GDP by the GTPase domain, one of the two domains within the Gα subunit 
(step E). The Gα subunit then re-associates with the Gβγ dimer, terminating the signal (step F), 
thus resetting the catalytic cell cycle. 
While the process of GPCR regulated signaling is well understood, much less is known 
about the intracellular G proteins. The primary means by which the biochemistry community 
analyzes G protein function is through genetic manipulation where changes are made to 
individual amino acids within the G protein in order to examine the resulting changes in the 
signaling pathway. This approach is challenging due to the complexity of GPCR/G protein pairs 
and cellular adaptations to the genetic modifications, such as the rewiring of signaling 
pathways.5,6 These challenges, coupled with the knowledge that roughly 10-15% of all cancers 
are driven by a constitutively active mutant G protein α-subunit (step D), make alternative 
strategies for gaining insight into the GPCR signaling pathways attractive. Among these 
alternatives, molecules that selectively bind in a reversible manner and inhibit intracellular G 
proteins can serve as invaluable probes of specific G protein signaling pathways and as potential 
starting points for the development of new therapeutics. For this reason, such molecules are 
important synthetic targets.7 
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1.2 Targeting Intracellular G Proteins 
To date, only a handful of molecules directly target intracellular G proteins. Two such 
molecules are pertussis toxin and cholera toxin that covalently bind to Gαi and Gαs respectively 
and have been used to map these cell signaling pathways.8,9 In addition, the natural products 
YM-254890 (YM) and FR900359 (FR) (Figure 1.2) are known to potently and selectively bind 
to Gαq/11
 
in a pseudo-irreversible manner, trapping the α-subunit in its inactive GDP-bound 
state. These two natural products and their respective analogs are the only molecules known to 
behave in this manner. 
 
Figure 1.2 – YM-254890 & FR900359  
YM and FR were isolated from Chromobacterium sp. QS366 and the ornamental plant 
Ardisia crenata, respectively. They are both cyclic depsipeptides comprised of seven different 
amino acids, a twenty-two membered macrocycle, with eleven different stereocenters, and 
multiple ester, amide, and NMe amide bonds. The core structures of YM and FR differ in only 
two areas, highlighted red in Figure 1.2. FR contains a β-hydroxy leucine within the “bottom 
bridge” of macrocycle (compared to a threonine within YM) and a propionate derivative on the 
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β-hydroxy leucine tail of the macrocycle (compared to an acetyl residue found in YM). These 
two slight changes impart a three-fold increase in potency found in FR.11 While YM and FR are 
promising lead molecules, they are not isolated in high yields from natural sources, and efforts to 
synthesize these molecules in lab have primarily relied on solid state peptide chemistry. While a 
combination of solution phase and solid-state peptide chemistry has allowed for the completion 
of structure activity relationship (SAR) studies involving these molecules, it has not led to the 
generation of either of the natural products or their respective analogs in high yield.10-14 To this 
end, we propose a scalable synthesis of YM and FR analogs through a convergent route via 
exclusively solution-phase synthesis. Prior to the discussion of this synthesis, we should first 
focus on the knowledge available from SAR studies following isolation and synthesis of a 
variety of analogs of YM and FR. All available information is important for guiding the design 
and synthesis of new analogs. It is important to note that much of this information has become 
available during our synthetic efforts that will be discussed in Chapter 2. 
1.3 What We Know So Far 
To date, fifteen different analogs of FR have been synthesized or isolated, and more than 
35 different analogs of YM.14 While no analogs have been found with improved potency and 
efficacy over that of the natural product FR, much has been learned about what portions of this 
molecule appear to be necessary for binding. We will discuss these changes from left to right in 
individual amino acids labeled in Figure 1.3.  
Changes of the iso-propyl groups of β-HyLeu1 (often referred to as the β-hydroxy 
leucine tail) and β-HyLeu2 are not well tolerated and result in loss of potency and efficacy in 
comparison to the parent compound. However, in β-HyLeu1 multiple analogs with changes at 
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the acetyl group (R = CH3, CH2CH3, CH2SCH3) have been isolated and screened with minimal 
observed change in activity.10,15 
 
Figure 1.3 – Labeled YM & FR Structure 
Changes within the N-MeAla3 and Ala4 have been shown to be tolerated. The methyl 
groups of the alanine have been substituted with phenyl rings resulting in no significant loss in 
activity. This information is consistent with the observation that the top bridge of the molecule is 
solvent exposed and resides outside of the binding region within Gαq. This is particularly 
relevant as these sites may prove suitable for future installation of cross-linking moieties to add 
conformational rigidity to simplified analogs or fluorescent groups for various biological 
assays.12 The N-MeDha may provide a necessary conformational constraint, as illustrated by the 
subsequent loss in activity following the hydrogenation of the double bond. It is worth noting 
there is a significant disparity in activity between the resulting N-MeAla and N-Me-D-Ala. 
Hydrogenation leading to N-MeAla lead to a 16 fold loss in potency in comparison to the natural 
product YM, where a 160 fold loss in potency is observed in the case of N-Me-D-Ala.10,15 The 
difference between YM and FR, an Ac-Thr7 and Ac-β-HyLeu7, imparts three-fold more 
potency to FR. Lastly, changing the N-Me amide to a typical amide bond of the N-
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MeThr(OMe)8 results in a nearly 500 fold loss in potency as compared to the natural product 
YM.10 With this knowledge in hand we can now discuss a scalable synthesis of YM and FR 
analogs through a convergent route via solution phase synthesis. 
1.4 Scaling through Simplified Analogs 
The use of a Function Oriented Synthesis was made popular by Paul Wender and 
coworkers in their synthesis of Bryostatin analogs, although this overall strategy has been 
employed by medicinal chemists for many years.16 While this idea will not be discussed at length 
here, the main concept is to retain the pharmacophore within a complex natural product, while 
stripping away some of its functionality, thus shortening the overall total synthesis. This was 
accomplished in the synthesis of simplified analogs of Bryostatin, shortening the synthesis of the 
molecule from more than seventy steps, to less than thirty.17,18 
 
Figure 1.4 – YM-254890 & WU-07047 Structures 
This strategy was first applied to the synthesis of simplified analogs of YM by Rensing 
et. al. from our group. Their approach is highlighted in Figure 1.4. The red regions represent 
regions of YM that were shown to bind to Gαq in an X-ray crystal structure of YM-Gαq 
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complex.19 The asterisks represent direct points of contact within Gαq, and the numbers indicate 
intramolecular hydrogen bonds meant to stabilize the binding conformation of YM to Gαq. The 
intent was to simplify the groups bridging the points of contact with simplified alky chains and 
alkene units that would participate in a ring closing metathesis reaction.5  
While the first simplified analogs were synthesized, leading to initial screens of 
biological activity, there were many challenges within the first-generation synthesis that still 
needed to be addressed. Namely a problematic β-elimination involving the side chain on the left-
hand side of the molecule as drawn (sometimes referred to as the β-hydroxy leucine tail). This β-
elimination resulted in a lowering of yields for every reaction in the synthesis following the 
introduction of the side chain via esterification to acyclic molecule, inevitably making the 
synthesis very difficult to repeat. With the intent of not only devising analogs that improve 
efficacy, but also scaling the synthesis of those analogs for use in animal models, it became clear 
that we must first address this elimination. The methods used to solve this problem, as well as 
efforts to improve the potency and efficacy of analogs that target Gαq, will be discussed in the 
following chapters. Greater detail about the initial approach and the issues encountered will be 
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Chapter 2: Synthesis of Simplified Analogs 
2.1 First Generation Synthesis 
Through the use of a convergent synthesis as outlined by Rensing et. al., the first 
simplified analog of YM-254890 (YM) was accomplished providing analog WU-07047 (WU) 
with a longest linear sequence of 10 steps and an overall yield of 6.4%. The retrosynthetic 
analysis from the first-generation synthesis discussed in chapter one is outlined in Figure 2.1. 
 
Figure 2.1 Retrosynthetic Analysis of WU-07047 
With this analog in hand, WU was screened for its ability to inhibit nucleotide exchange 
in Gαq and then compared with the activity associated with the natural product, YM. While this 
first-generation simplified analog retained selectivity towards Gαq, it was much less potent then 
the natural product and did not retain full efficacy.1 Still, the selectivity observed towards Gαq 
suggests that it may serve as a great starting point for the synthesis of future analogs. For our 
part, we are interested in synthesizing chemical probes for mapping the GPCR signaling 
pathways. To best probe this cell signaling pathway it is of paramount importance to obtain not 
only potent analogs, but analogs that retain selectivity and efficacy (evidence that the mechanism 
11 
 
of action of the simplified analog is similar to that of the natural product). With this in mind, a 
second look at our first-generation synthesis suggested that reproducing this synthetic route, 
varying the analogs made, and scaling the reactions to increase the amount of product isolated 
would prove quite challenging. The isolation of nearly 80 mgs of WU from the initial efforts was 
indeed a leap forward compared to the trace amounts (1.0 – 3.2 mgs) of material isolated through 
solid-state peptide chemistry2-4, but despite literature precedent, the addition of the β-hydroxy 
leucine (highlighted red in Figure 2.1) side chain in the early stages of the synthesis led to 
significant losses in material along the way. 
 
Figure 2.2 A Problematic β-Elimination 
In the hands of an experienced synthetic organic chemist, it is possible to complete the 
synthesis of analog WU by rapidly assembling the macrocycle. However, this sequence is 
plagued with a β-elimination shown in Figure 2.2 at every step of the synthesis following 
incorporation of the β-hydroxyleucine side chain prior to the formation of the macrocycle. In 
order to continue to produce new analogs in a scalable fashion, it became evident we must first 
turn our attention to solving the problem of this β-elimination. It was apparent that this could be 




2.2 Avoiding the β-Elimination 
Since the natural product could be isolated without any evidence of the undesired β-
elimination, we believed it possible to add the β-hydroxy leucine sidechain in the final step of 
our total synthesis. This idea was solidified by the experimental observation that the β-
elimination did not occur following formation of the macrocycle in the synthesis of the first 
simplified analog WU. Interestingly, a molecular dynamics minimization of both WU and YM 
using ChemBio 3D showed that in the macrocyclic products the proton responsible for this β-
elimination is not antiperiplanar to the ester leaving group and hence not oriented in a fashion 
necessary for the elimination to readily occur (Figure 2.3). This arrangement is not observed in 
the acyclic molecules where free rotation allows for the necessary antiperiplanar arrangement of 
the bonds involved in the elimination reaction. 




In the end, molecular dynamics calculations and the experimental observations appear to 
confirm our hypothesis that a strategy that places the β-hydroxyleucine side chain on last 
following synthesis of the intact macrocycle could be successful. This analysis has led to the 
retrosynthetic approach shown in Figure 2.4. One attractive feature of this approach is that it 
does not vary our synthetic strategy significantly from the synthesis accomplished by Rensing et. 
al. 
 
Figure 2.4 – Second Generation Retrosynthetic Analysis 
Upon removal of the final β-hydroxyleucine moiety in the retrosynthesis, the left-hand 
portion of the macrocycle (A) is still a β-hydroxy leucine derivative that is protected with a C-
terminal ester and coupled to an extended amino acid derivative. The right-hand portion (B) of 
this molecule is the same coupled product of an allylglycine with a 2-hydroxy-3-phenylpropionic 
acid derivative that was used in the first-generation synthesis. The macrocycle would be 
constructed from a standard coupling of left- and right-hand portions of this macrocycle followed 
by the same olefin metathesis strategy used previously. 
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While this change may look trivial, there was no evidence in the literature of a synthetic 
approach that allows for the addition of the β-hydroxyleucine side chain last. We believe this is 
due to the N-Acetyl protecting group on the nitrogen of the β-hydroxyleucine side chain in the 
natural product. This acetyl protecting group is not orthogonal with standard coupling 
procedures. The challenges associated with this coupling will force us to either devise a new 
coupling strategy, find an alternative protecting group, or exchange a protecting group in the 
final steps of a total synthesis (the least appealing of the possible approaches). We began with 
the assembly of the macrocycle, before addressing the challenges associated with solving this β-
elimination. 
2.3 Right Hand Piece (RHP) Synthesis 
 
 
Scheme 2.1 – RHP Synthesis 
The synthesis of the right-hand portion of the molecule began with a commercially 
available (S) allyl-glycine (Scheme 2.1). The availability of this starting material removed the 
need to synthesize the allyl-glycine using an asymmetric Ireland Claisen rearrangement from the 
first-generation synthesis. The acylation of the amine afforded compound 2.1 in 73% percent 
yield. The carboxylic acid was then subjected to Mitsunobu coupling to a methyl (S)-2-hydroxy-
3-phenylpropionate affording coupled product in a 93% yield. It is worth noting this Mitsunobu 
reaction serves two purposes. First, the reaction proceeds with stereo inversion since in the 
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mechanism the hydroxyl group is first converted to a leaving group and then displaced by the 
acid in an SN2-type reaction. In addition, this coupling strategy is also compatible with the 
presence of the N-acetyl protecting group on the nitrogen. Under standard coupling conditions, 
the activated carboxylic acid intermediate is attacked by the nucleophilic oxygen of the acetyl 
group resulting primarily in oxazolone formation (Figure 2.5). 
 
Figure 2.5 – Mitsunobu vs. Standard Coupling 
Upon completion of the Mitsunobu reaction, the methyl ester was cleaved using LiI in 
refluxing THF as developed by Dr. Derek Rensing. This approach not only resulted in minimal 
racemization (confirmed by HNMR) but also provided a 69% yield of compound 2.3 that was 
then purified via recrystallization.  
With this basic strategy in place, we turned our attention to making further analogs of this 
right-hand building block. To do so, we chose to protect the N-terminus of the allyl-glycine with 
an ethyl carbamate in place of the N-acetyl group found in the natural product. This alternate 
protection strategy would serve two purposes. First, it would improve yields relative to the 
acylation reaction that led to inconsistent yields during the production of compound 2.1. Second, 
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it would allow us to use an esterification reaction in place of the Mitsunobu coupling. As the 
esterification reaction will not invert the stereochemistry of the alcohol like the Mitsunobu 
reaction, this will provide an opportunity to probe how changes to this stereocenter might alter 
the biological behavior of the natural product. What role does this stereocenter play in the 
selectivity of the natural product for Gqα? 
 
Scheme 2.2 – RHP Synthesis Continued 
Following the protection of the allyl glycine derivative with ethyl chloroformate (Scheme 
2.2), compound 2.4 could then be subjected to standard esterification conditions with TBTU, 
resulting in an 89% yield of compound 2.5b, a product that retains the stereocenter found in the 
methyl (S)-2-hydroxy-3-phenylpropionate. To obtain the stereocenter found in the natural 
product we subjected compound 2.4 to Mitsunobu conditions, affording an 85% yield of 
compound 2.5a. Both methyl ester substrates were then treated with LiI in THF to afford the 
acid needed for the subsequent coupling reaction. It is worth noting the increase in yields, as well 
as an improvement in consistency of yields, across this sequence of reactions when the ethyl 
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carbamate protected amine was used in place of the acetamide. While the use of the ethyl 
carbamate may require exchanging protecting groups later in the synthesis, we hoped that 
analogs with the carbamate intact may retain sufficient activity as to make this additional 
transformation unnecessary.  
With multiple derivates of the right-hand portion now available (and a synthetic route in 
place to make others), we turned our attention to the assembly of the building block containing 
both the simplified top bridge and the left-hand portion of the macrocycle (Scheme 2.3). 
2.4 Left Hand Piece (LHP) Synthesis 
 
 
Scheme 2.3 – LHP Synthesis 
The synthesis of the left-hand portion of the molecule prior to the addition of the 
sidechain did not vary from the first-generation synthesis (Scheme 2.3). To this end, the C-
terminus of an extended alkyl chain amino acid derivative was activated with isobutyl 
chloroformate and N-methylmorpholine, and the resulting mixed anhydride treated with β-
hydroxy leucine in 1 M NaOH, to afford the thermodynamic amide coupling product 2-11 in 
93% yield. The new C-terminus of the molecule was then converted to the allyl ester providing 
the alkene necessary for the eventual ring closing metathesis. At this point we chose to leave the 
free hydroxyl group in compound 2-12 unprotected, hoping this would not interfere with the 
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coupling of our left- and right-hand portions of the molecule to make the precursor for the 
metathesis reaction. The idea was that amide bond formation would be preferred over the 
formation of an ester based on both the nucleophilicity of the amine and the stability of the 
amide product. With the building blocks of our simplified analog assembled, it was time to turn 
our attention to the synthesis of the macrocycle. 
2.5 Macrocycle Synthesis 
 
 
Scheme 2.4 – Macrocycle Synthesis 
The assembly of the macrocycle (Scheme 2.4) began with the treatment of the left-hand 
portion of our molecule (2-12) with standard Boc deprotection conditions using TFA. Following 
the Boc deprotection, the crude product was carried forward without isolation as the 
trifluoroacetate salt of the amine. The trifluoroacetate salt of compound 2-12 was treated with 
HATU, DIPEA in DMF, and the previously synthesized right-hand piece of the molecule (2-6a). 
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The use of these coupling conditions was chosen following a screening of the standard coupling 
conditions highlighted in Table 2.1. 
Table 2.1 – Macrocycle Coupling Optimization 
 
Following purification, compound 2-15a was isolated in a 64% yield. No evidence was 
obtained for an esterification product that was the result of a coupling reaction with the 
unprotected alcohol in compound 2-12. This acyclic molecule was then treated with Grubbs 
Generation II catalyst (Scheme 2.4) to afford compound 2-16a in 59% yield. With the 
macrocycle intact, we could now turn our attention to one of two strategies to add the final β-
hydroxy leucine side chain. 
2.6 β-Lactone Strategy 
In order to couple the final β-hydroxyleucine moiety, we believed we could employ a 
similar approach to the “β-Lactam Synthon Method” used by Ojima and coworkers to complete 




Figure 2.6 – β-Lactam Approach to Taxol 
The use of a similar β-lactone based strategy in our case was suggested for two reasons. 
First, we hoped that the use of a strained four membered ring may provide sufficient driving 
force for the coupling of a challenging ester bond in a way that allowed for more gentle reaction 
conditions, thus avoiding any chance of the β-elimination reaction. Second, the use of the lactone 
would allow us to avoid the juggling of protecting groups necessary for a standard esterification 
reaction in the presence of the alcohol in the β-hydroxyleucine sidechain (Figure 2.7).  
  
Figure 2.7 – Coupling Strategies 
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This approach leads to a shorter synthetic strategy (Path A) that would save multiple 
steps relative to the more standard esterification and reduce the loss of the our most expensive 
substrate. The β-hydroxyleucine costs over $1,000 for 500 mgs, the common scale of material at 
the start of these protecting group sequences. Due to the significant cost of β-hydroxyleucine, we 
synthesize the material “in house” as highlighted in Scheme 2-8, which we will revisit later this 
chapter. Prior to this discussion, we will first focus on the synthesis of β-lactones. 
 
 
Scheme 2.5 – β-Lactone Synthesis 
The synthesis of this β-lactone began with the protection of the β-hydroxy leucine with 
methyl chloroformate affording compound 2-7 in 89% yield (Scheme 2.5). The use of a methyl 
carbamate as a protecting group was chosen in the hopes of avoiding the exchange of protecting 
groups to the acetyl group found in the natural product late in the synthesis. We believed there to 
be a high chance of biological tolerance due to the isolation of derivatives of the natural product 
with alternative protecting groups on the β-hydroxyleucine side chain.3-7 This material was 
isolated based upon its carboxylic acid and was carried forward without further purification. The 
synthesis of the β-lactone was accomplished with the coupling agent TBTU and triethylamine in 
DCM as outlined by Vitale et. al.8 This reaction was run at very dilute conditions in order to 
avoid the bi-molecular esterification. The β-hydroxy lactone was then purified via flash column 
chromatography to afford 75% yield of expected product. 
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With the intent of making a variety of analogs we believed it to be possible to diversify in 
the last step of our synthesis. In order to probe the tolerance of protecting groups and side chains, 
a variety of β-lactones were synthesized (Table 2.2). These amino acids were chosen due to ease 
of synthesis and commercial availability. Following the synthesis of our macrocycle, this diverse 
array of β-lactones would allow us to rapidly make a variety of analogs via the final esterification 
reaction.  
Table 2.2 – β-Lactones 
With these β-lactones in hand we turned out attention to devising a mock substrate 
system to screen conditions for the lactone opening. We hoped to avoid having to use the 
macrocycle as it was synthetically more advanced. Unfortunately, all mock substrates suffered 




Figure 2.8 – Substrate Screening 
This elimination proved quite challenging when trying to access the success of reaction. 
The screening of conditions began with previously synthesized compound 2-12. This material 
was chosen as it was readily available and would most closely resemble the macrocycle. 
Screening began with the use of NaHMDS, the same base used in the semi-synthesis of taxol.2 
The use of an excess of a strong base, none to surprisingly, lead to exclusively β-elimination 
product, though pleasingly we found evidence of successful coupling in the proton NMR when 
the equivalents of base were decreased (Table 2.3). This led to the suggestion of the use of a 
catalytic base system in an attempt to slow the elimination. The use of DBU:Triazole in a 
catalytic fashion led to further evidence of product formation, however, rapid decomposition of 
the product due to the β-elimination led to problems isolating the desired product.  
 




This information led us to conclude that it would be necessary to test the esterification 
conditions using the intact macrocycle. Following the synthesis of the macrocycle, we were able 
to isolate trace amounts of the desired coupled product, but we were never able to bring obtain 
satisfactory yields of the product in a reproducible fashion. It is worth noting that during the 
screening of bases for the reaction, no evidence was found for the problematic β-elimination 
either in proton NMR of the crude material or in the products isolated following purification of 
the crude product. With no evidence of the β-elimination yet a very poor mass balance, we were 
quite troubled. It appears that the low mass balance is due to a polymerization of the ring opened 
β-lactone (Figure 2.9). 
 
Figure 2.9 – Lactone Polymerization 
To this end, opening of the β-lactone leads to a hydroxy anion is then capable of opening 
a second lactone. Of course, that ring opening would again lead to an alkoxide capable of 
opening a third lactone, and so forth and so on. Each product from the lactone opening can either 
continue this chain process or undergo a separate β-elimination. We made several attempts to 
control this polymerization. We began with varying the temperature of the reaction, monitoring 
completion of the reaction via TLC at -78 °C, 0 °C, and RT. This led to no observable change in 
yields. As we were able to recover our macrocycle starting material, we decided to use an excess 
of this starting material in an attempt to slow the polymerization. This, in conjunction with 
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addition of the lactone dropwise to the macrocyle over a 30-minute period did slightly improve 
yields. These yields which remained unacceptable from a synthetic standpoint are highlighted in 
Table 2.3. Unfortunately, it appears the β-hydroxyleucine side chain is less sterically hindered 
than the macrocycle, resulting in this polymerization because the extension of the chain is more 
rapid than the initial coupling reaction. As the struggles with this polymerization continued to 
occur, we chose to turn our attention to standard esterification conditions to add the β-
hydroxyleucine side chain. This route may be longer, but if it can be consistently reproduced in 
higher yields, then it would be preferable compared to that of the inconsistent β-lactone 
approach. In addition to the protection strategy to be discussed below, future efforts to control 
the rate of this polymerization reaction include the use of a TBS trapping group, and acid 
catalysis. 
2.7 β-Hydroxyleucine Protection Strategy 
 
 
Scheme 2.6 – β-Hydroxy Leucine Protection Strategy 
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This less elegant strategy began with the use of methyl chloroformate to protect the free 
amine in our β-hydroxyleucine starting material to afford compound 2-7 in an 89% yield 
(Scheme 2.6). The carboxylic acid was then protected in the presence of the free hydroxyl group 
using benzyl bromide and cesium carbamate. This protecting group was chosen as opposed to the 
allyl ester in the first-generation synthesis due to its ease of removal.1 The removal of the allyl 
protecting group relied on the use of a Pd(0) catalyst. The yields of this deprotection were 
inconsistent and depended highly on the quality of the catalyst that aged quickly. Yields could be 
improved with activation of the catalyst using n-BuLi, but inconsistency was still a significant 
challenge. Following the protection of the acid, the free hydroxyl group was then protected using 
TBDMS triflate, affording compound 2-9 in a 98% yield. Last, the benzyl group was cleaved 
using standard hydrogenation conditions. The resulting carboxylic acid was carried forward to 
the next step without further purification. 
 
Scheme 2.7 – Macrocycle Esterification 
The β-hydroxyleucine side chain was added to the macrocycle using the reaction 
sequence shown in Scheme 2.7. This was accomplished by treating the macrocycle (2-16a) with 
EDC, catalytic DMAP, and the crude carboxylic acid (2-10) as highlighted above. A catalytic 
amount of DMAP was used for the reaction in order to avoid conditions that were too basic. 
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Again, we were concerned with the possibility of a β-elimination reaction following the 
esterification, although there was no evidence of this elimination in either the isolated product or 
the proton NMR of the crude reaction product. Following purification, the esterification reaction 
afforded a 50% yield of compound 2-18a, which was then treated with TBAF to remove the 
TBDMS protecting group. After deprotection, the resulting alcohol, compound 2-19a, was 
isolated in a 55% yield. 
 In order to ensure this synthesis was as efficient as possible, we decided to determine the 
necessity of purification and isolation of intermediate 2-18a. Following the esterification 
reaction, the crude coupled product was then treated with TBAF. After purification, the desired 
product was isolated in a 40% yield over two steps. A comparison of yields seems to indicate it 
is unnecessary to isolate the coupled product prior to the subsequent TBDMS deprotection. At 
this point, the methyl carbamate was left in place and was not exchanged for the N-acetyl group 
found in the natural products. A topic that will be discussed in further detail in Chapter 3. 
2.8 β-Hydroxyleucine Synthesis 
 
Scheme 2.8 – β-Hydroxyleucine 
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 The synthesis of the syn-β-hydroxyleucine was accomplished according to literature 
protocol (Scheme 2.8).9 The syn-β-hydroxyleucine was isolated in a 35% overall yield over five 
steps. 
 This concludes the discussion regarding the synthetic efforts made to complete the 
second-generation simplified analogs. We will now turn our attention to the lessons learned from 
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2.10 Experimental Procedures 
General Procedures: 
Methyl Ester Deprotection 
To a flame dried round bottom flask with stir bar was added lithium iodide (7.07 mmol) in THF 
16 mL. The flask was then brought to reflux before addition of methyl ester (1.86 mmol) in THF 
(15 mL). The flask was then refluxed for 24-48h. After 24-48h, the reaction was allowed to cool 
to room temperature before concentrating. The resulting oil was dissolved in 50 mL chloroform 
and extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then 
brought to pH=2 and extracted with chloroform (3x30 mL). The combined organic layers were 
then dried with MgSO4 and concentrated in vacuo. 
Mitsunobu Esterification 
Carboxylic acid (1.80 mmol), was subjected to a benzene (30 mL) azeotropic distillation to 
remove any trace water. To this flask were added triphenylphosphine (1.80 mmol), followed by 4 
mL THF. The flask was stirred at -30 °C before addition of alcohol (1.64 mmol) dissolved in an 
additional 4 mL THF, followed by dropwise addition of 0.84 mL (1.84 mmol) of a 40 wt % 
solution of diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30 
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction 
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was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with 
saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with EtOAc (2x20 
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The 
resulting oil was purified via flash column chromatography. 
Ring Closing Metathesis 
To a flame dried RBF was added the acyclic diene (0.25 mmol) in DCM (160 mL). The reaction 
was brought to reflux before addition of Grubbs gen. II Catalyst (0.05 mmol) in DCM (15 mL). 
After 20 hours at reflux, the reaction was allowed to cool to RT before concentration in vacuo. 
The resulting crude brown oil was then purified via flash column chromatography.  
Macrocycle Esterification 
To a flame dried RBF was added 0.1979 g (0.32 mmol) macrocycle with 0.0102 g (0.08 mmol) 
DMAP and 0.0917 g (0.48 mmol) EDC. The flask was cooled to 0 °C before addition of 0.1296 
g (0.40 mmol) compound 7d in DCM (2.5 mL). The reaction was then stirred and allowed to 
reach RT overnight. After 48h the reaction was diluted with DCM (30 mL) and washed with 
saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with DCM (2x20 
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The 
resulting oil was then purified via flash column chromatography. 
Amide Coupling (HATU) 
To a flame dried RBF was added 0.057 g (0.14 mmol) boc-protected amine, which was stirred at 
room temperature in dichloromethane (3 mL) with trifluoracetic acid (1 mL). After three hours 
the reaction was diluted with diethyl ether (20 mL) and concentrated in vacuo. This dilution and 
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concentration were repeated three times, followed by azeotropic distillation with benzene (25 
mL) in order to remove any trace water. To this flask was then added 0.0520 g (0.17 mmol) 
carboxylic acid with 0.0798 g (0.21 mmol) HATU. The contents of the flask were then dissolved 
in DMF (1 mL), followed by addition of 0.06 mL (0.34 mmol) DIPEA. The reaction was then 
stirred at RT overnight. After 20 hours the reaction was diluted with EtOAc (30 mL) and washed 
with saturated NaHCO3 (3x25 mL). The aqueous layer was then back extracted with EtOAc 
(2x20 mL). The combined organic layers were then dried with MgSO4 and concentrated in 
vacuo. The resulting oil was then purified via flash column chromatography. 
TBDMS Deprotection 
A stirring solution of 0.0135 g (0.015 mmol) TBS protected alcohol in THF (0.35 mL) was 
brought to 0 °C before addition of 0.05 mL (0.045 mmol) 1 M TBAF solution in THF. After 30 
minutes, the reaction was quenched with saturated ammonium chloride (15 mL). The aqueous 
layer was then extracted with EtOAc (3x20 mL). The combined organic layers were then dried 
with MgSO4 and concentrated in vacuo. The resulting oil was then purified via flash column 
chromatography. 
Lactone Formation 
The β-hydroxy acid, 0.5258 g (2.13 mmol) was added to a flame dried flask with 0.8155 g (2.54 
mmol) TBTU. The compounds were then dissolved in 100 mL DCM and stirred at room 
temperature prior to addition of 0.92 mL triethylamine. After 20 hours the reaction was washed 
with saturated NaHCO3 (3x35 mL). The aqueous layer was then back extracted with DCM (2x30 
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The 





[Compound 2-1] A stirring solution of 0.499 g (4.33 mmol) L-allylglycine in 15 mL H2O was 
brought to 0 °C. The pH was adjusted to pH=10 with 1 M NaOH. 0.46 mL (4.74 mmol) freshly 
distilled Acetic Anhydride was then added dropwise to the stirring solution. The pH was re-
adjusted to 10 and was allowed to stir and reach room temperature overnight. After 18 hours, the 
reaction was brought to pH=2 with 1 M HCl. The reaction was then extracted with EtOAc (3x30 
mL). The organic layer was then dried with MgSO4 and concentrated in vacuo to afford 0.5000 g 
(73% yield) of compound 2-1 as a white solid. This crude product was carried forward without 
any further purification.  
1H NMR (500 MHz, Chloroform-d) δ 11.50 (br, 1H), 6.32 (d, J = 7.6 Hz, 1H), 5.66 (ddt, J = 
16.5, 10.4, 7.2 Hz, 1H), 5.25 – 4.95 (d, 2H), 4.73 – 4.47 (m, 1H), 2.74 – 2.37 (m, 2H), 2.02 (s, 
3H); 13C NMR (126 MHz, Chloroform-d) δ 173.40, 170.27, 131.02, 118.45, 50.85, 35.03, 21.84. 
Full characterization has been previously reported.1 
 
[Compound 2-2] The reaction was set up according to General Procedure: Mistunobu 
Esterification. The crude product was then purified by flash chromatography (silica gel, 100% 
Et2O) to give 0.7390g (93% yield) of compound 2-2 as a white solid.  
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1H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.19 (m, 5H), 5.88 (d, J = 7.9 Hz, 1H), 5.40 (ddt, J 
= 17.2, 10.2, 7.2 Hz, 1H), 5.25 (dd, J = 9.5, 4.0 Hz, 1H), 5.00 – 4.95 (dd, 1H), 4.84-4.77 (m, 2H), 
3.76 (s, 3H), 3.25 (dd, J = 14.3, 4.0 Hz, 1H), 3.15 – 3.08 (dd, 1H), 2.48 (m, 1H), 2.35 (m, 1H), 
1.98 (s, 3H); 13C NMR (126 MHz, Chloroform-d) δ 173.72, 172.07, 172.03, 138.25, 134.40, 
131.89, 131.89, 131.87, 131.26, 129.89, 121.90, 76.40, 55.19, 54.16, 39.93, 38.88, 25.76. Full 
characterization has been previously reported.1 
 
[Compound 2-3] The reaction was set up according to general procedure, Methyl Ester 
Deprotection. After refluxing for 24 hours the reaction was worked up as seen in the general 
procedure, Methyl Ester Deprotection. 0.2389 g (69% yield) of compound 2-3 as a yellow oil. 
Recrystallization in EtOAc, followed by slow evaporation in MeOH affords pure diastereomer as 
clear crystals. 
1H NMR (500 MHz, Methanol-d4) δ 7.34 – 7.19 (m, 5H), 5.61 (ddt, J = 14.1, 10.3, 7.1 Hz, 1H), 
5.19 (dd, J = 9.4, 3.9, 1.9 Hz, 1H), 5.02 (dd, 1H) 4.98 - 4.91 (dd, 2H), 4.54 (td, J = 7.5, 5.3, 2.1 
Hz, 1H), 3.25 (dd, J = 14.4, 3.8 Hz, 1H), 3.09 (dd, J = 14.4, 9.3, 1.9 Hz, 1H), 2.44-2.31 (m, 2H), 
1.93 (s, J = 2.0 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 174.29, 173.72, 173.47, 138.93, 
135.31, 135.26, 131.72, 130.77, 129.37, 129.26, 120.06, 76.22, 54.70, 39.50, 38.05, 23.58. Full 




[Compound 2-4] To a flame dried round bottom flask were added 0.501 g (4.36 mmol) L-
allylglycine, and 0.915 g (10.9 mmol) NaHCO3. The flask was brought to 0 °C before  addition 
of 17.5 mL THF, followed by 11.3 mL of H2O. In two separate portions, 2.1 mL (21.8 mmol) of 
Ethyl chloroformate was added over thirty minutes. The flask was allowed to stir and reach room 
temperature overnight. After 20 hours, the reaction was diluted with H2O (30 mL) and then 
washed with EtOAc (3x30 mL). The organic layer was then back extracted with saturated 
NaHCO3 (2x25 mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl 
and extracted with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4 
and concentrated in vacuo to afford 0.7313 g (90% yield) of compound 2-4 as a clear oil. This 
crude product was carried forward without any further purification. 
FTIR (neat) 3324, 2983, 1694, 1519, 1419, 1381, 1339, 1220, 1096, 1054 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 10.73 (s, 1H), 5.74 (dq, J = 16.9, 7.9 Hz, 1H), 5.38 (d, J = 8.2 Hz, 1H), 
5.16 (dd, J = 13.7, 8.6 Hz, 2H), 4.46 (q, J = 6.7 Hz, 1H), 4.15 (dq, J = 21.6, 7.3 Hz, 2H), 2.58 
(dt, J = 40.4, 15.1, 6.9 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 
176.12, 156.42, 132.04, 119.47, 61.48, 53.08, 36.42, 14.47; HRMS m/z calculated for 
C8H13O4N1 [M+Na]




[Compound 2-5a] The reaction was set up according to general procedure, Mitsunobu 
Esterification. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.484 g (85% yield) of compound 2-5a as a white solid. 
FTIR (neat) 3325, 2982, 1743, 1720, 1524, 1439, 1376, 2338, 1196, 1060 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 7.30 – 7.19 (m, 5H), 5.44 (m, J = 17.1, 7.8 Hz, 1H), 5.25 (dd, J = 9.5, 4.0 
Hz, 1H), 5.11 (d, J = 8.4 Hz, 1H), 4.98 (d, J = 10.2 Hz, 1H), 4.87 (d, J = 17.0 Hz, 1H), 4.51 (q, J 
= 6.4 Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 3.74 (s, 3H), 3.23 (dd, J = 14.3, 4.0 Hz, 1H), 3.09 (dd, J 
= 14.3, 9.4 Hz, 1H), 2.45 (dt, J = 13.5, 6.3 Hz, 1H), 2.35 (dt, J = 13.8, 6.6 Hz, 1H), 1.24 (t, J = 
7.2 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) δ 171.09, 169.45, 155.73, 135.63, 131.71, 
129.24, 128.58, 127.19, 119.33, 73.69, 61.14, 53.02, 52.49, 37.32, 36.53, 14.53; HRMS m/z 
calculated for C18H23O6N1 [M+Na]
+ 372.1418, 372.1413 observed. 
 
[Compound 2-6a] The reaction was set up according to general procedure, Methyl Ester 
Deprotection. After refluxing for 48 hours the reaction was worked up as seen in the general 
procedure, Methyl Ester Deprotection. 0.3516 g (82% yield) compound 2-6a as a clear oil was 
carried forward without any further purification. 
FTIR (neat) 3324, 2982, 1717, 1519, 1437, 1377, 1339, 1187, 1061 cm-1; 1H NMR (500 MHz, 
Methanol-d4) δ 7.33 – 7.21 (m, 5H), 5.62 (m, J = 17.2, 10.3, 7.0 Hz, 1H), 5.19 (t, J = 9.3, 3.8 Hz, 
1H), 5.02 – 4.92 (m, 2H), 4.29 (t, J = 8.2, 5.1 Hz, 1H), 4.06 (t, J = 7.1, 2.6 Hz, 2H), 3.25 (dd, J = 
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14.3, 3.9 Hz, 1H), 3.10 (dd, J = 14.3, 9.3 Hz, 1H), 2.46 – 2.41 (m, 1H), 2.30 (m, 1H), 1.25 (t, J = 
14.1, 7.1 Hz, 3H); 13C NMR (126 MHz, Methanol-d4) δ 
13C NMR (126 MHz, cd3od) δ 173.88, 
173.70, 159.76, 138.93, 135.42, 131.72, 131.72, 130.73, 130.73, 129.21, 120.01, 76.22, 63.31, 
56.31, 39.52, 38.27, 16.15; HRMS m/z calculated for C17H21O6N1 [M+Na]
+ 358.1261, 358.1276 
observed. 
 
[Compound 2-5b] To a flame dried RBF were added 0.803 g (2.50 mmol) TBTU and 0.3784 g 
(2.10 mmol) Methyl L-3-phenyllactate. This this flask was transferred 0.430 g (2.30 mmol) 
compound 2-4 in 15 mL Dichloromethane. The stirring solution was brought to 0 °C before 
dropwise addition of 0.91 mL (6.50 mmol) Triethylamine. The reaction was allowed to stir and 
reach RT overnight. After 20 hours the reaction was diluted with DCM (50 mL). The organic 
layer was then washed with saturated NaHCO3 (3x25 mL). The combined organic layer was then 
dried with MgSO4 and concentrated in vacuo. The resulting oil was then then purified by flash 
chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.650 g (89% yield) of 
compound 2-5b as a clear oil. 
FTIR (neat) 3324, 2982, 1721, 1523, 1439, 1379, 1341, 1191, 1064; 1H NMR (500 MHz, 
Chloroform-d) δ 7.32 – 7.18 (m, 5H), 5.71 (m, 1H), 5.28 (dd, J = 8.1, 4.6 Hz, 1H), 5.21 (d, J = 
8.5 Hz, 1H), 5.16 – 5.06 (m, 2H), 4.44 (m, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 3.12 (d, 
1H), 2.97 (d, J = 6.5 Hz, 1H), 2.55 (dd, J = 7.2, 6.6 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR 
(126 MHz, cdcl3) δ 177.18, 172.10, 158.60, 139.12, 134.79, 132.11, 131.93, 131.18, 131.17, 
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131.03, 122.07, 74.00, 63.79, 54.98, 43.22, 39.87, 39.13, 17.16; HRMS m/z calculated for 
C18H23O6N1 [M+Na]
+ 372.1418, 372.1412 observed. 
 
[Compound 2-6b] The reaction was set up according to general procedure, Methyl Ester 
Deprotection. After refluxing for 48 hours the reaction was worked up as seen in the general 
procedure, Methyl Ester Deprotection. After refluxing for 48 hours the reaction was worked up 
as seen in the general procedure, Methyl Ester Deprotection. 0.2454 g (63% yield) compound 2-
6b as a clear oil was carried forward without any further purification. 
FTIR (neat) 3362, 2947, 1836, 2506, 2074, 1700, 1439, 1379, 1275, 1188, 1118, 1023; 1H NMR 
(500 MHz, Methanol-d4) δ 7.34 – 7.18 (m, 5H), 5.77 (m, J = 18.5, 10.3, 7.7, 6.4 Hz, 1H), 5.23 
(ddd, J = 8.1, 4.3, 1.4 Hz, 1H), 5.14 – 5.02 (m, 2H), 4.90 (s, 3H), 4.25 (dd, J = 8.7, 5.0 Hz, 1H), 
4.11 – 4.03 (m, 2H), 3.32 (dq, J = 3.2, 1.6 Hz, 1H), 3.23 (dd, J = 14.4, 4.4 Hz, 1H), 3.18 – 3.08 
(m, 1H), 2.58 (ddd, J = 12.1, 9.2, 5.4 Hz, 1H), 2.47 – 2.36 (m, 1H), 1.24 (tdd, J = 7.0, 5.4, 1.3 
Hz, 3H); 13C NMR (126 MHz, cd3od) δ 174.04, 173.52, 159.87, 138.75, 135.78, 131.78, 130.68, 
130.47, 129.21, 128.75, 119.98, 76.06, 63.33, 56.10, 39.43, 38.11, 16.16; HRMS m/z calculated 
for C17H21O6N1 [M+Na]




[Compound 2-7] A stirred solution 0.5007 g (2.73 mmol) of the hydrochloride salt of β-hydroxy 
leucine with 0.6855 g (8.16 mmol) in 9 mL H2O was brought to 0 °C. 9 mL THF was then added 
to stirring solution, followed by 1.2 mL (16.3 mmol) methyl chloroformate in three 0.4 mL 
portions over the next 30 minutes. Reaction was allowed to stir and reach room temperature 
overnight. After 20 hours, the reaction was diluted with H2O (30 mL), and then washed with 
EtOAc (2x30 mL). The organic layer was then back extracted with saturated NaHCO3 (3x25 
mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl and extracted 
with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4 and 
concentrated en vacuo to give 0.4974 g (86% yield) compound 2-7 as a white foaming oil that 
was used without further purification. 
FTIR (neat) 3338, 2946, 2835, 2477, 2071, 1703, 1404, 1120, 1027 cm-1; 1H NMR (500 MHz, 
Chloroform-d) δ 6.03 (d, J = 9.6 Hz, 1H), 4.55 (d, J = 9.5 Hz, 1H), 3.85 – 3.77 (dd, 1H), 3.70 (s, 
3H), 1.83 – 1.72 (m, 1H), 1.03 (d, J = 6.7 Hz, 3H), 0.93 (d, J = 7.7 Hz, 3H); 13C NMR (126 
MHz, cdcl3) δ 178.47, 160.44, 80.19, 58.97, 55.31, 33.36, 21.77, 21.50; HRMS m/z calculated 
for C8H15O5N1 [M+Na]
+ 228.0842, 228.0852 observed. 
 
[Compound 2-8] To a stirred solution at room temperature of 0.2873 g (1.08 mmol) compound 
2-7 with 0.4352 g (1.35mmol) Cs2CO3 in 4.4 mL DMF was added 0.19 mL (1.62 mmol) benzyl 
bromide drop-wise. Reaction was stirred at room temperature overnight. After 24 hours, the 
reaction was diluted with 50 mL EtOAc. The organic layer was then washed with saturated 
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NaHCO3 (3x30 mL). The aqueous layer was then back extracted with EtOAc (2x20 mL). The 
combined organic layers were then dried with MgSO4 and concentrated in vacuo. The crude 
product was then purified by flash chromatography (silica gel, 75% Hexane:25% EtOAc) to give 
0.2588 g (81% yield) of compound 2-8 as a yellow oil.  
FTIR (neat) 3392, 2961, 1703, 1523, 1456, 1380, 1340, 1274, 1210, 1166, 1117, 1060, 1001 cm-
1; 1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.31 (m, 5H), 5.59 (d, J = 9.7 Hz, 1H), 5.20 (s, 
2H), 4.61 – 4.56 (d, 1H), 3.76 – 3.65 (m, 4H), 1.82 – 1.71 (m, 1H), 1.01 (d, J = 6.7 Hz, 3H), 0.95 
(d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 174.54, 159.95, 138.04, 131.26, 131.26, 
131.05, 130.76, 130.74, 80.16, 69.93, 58.94, 55.16, 33.47, 21.59, 21.53; HRMS m/z calculated 
for C15H21O5N1 [M+Na]
+ 318.1312, 318.1320 observed. 
 
[Compound 2-9] To a stirring solution of 0.2402 g (0.81 mmol) compound 2-8 in 5 mL DCM 
at 0 °C was added 0.47 mL (4.05 mmol) 2,6-Lutidine, followed by dropwise addition of 0.47 mL 
(2.03 mmol) TBDMS-triflate. Reaction was allowed to stir and reach RT overnight. After 24 
hours, the reaction was quenched with 1 M HCl (20 mL). Reaction was then extracted with DCM 
(3x25 mL). The combined organic layers were then washed with 1 M KHSO4(30 mL) and brine 
(30 mL). The organic layer was then dried with MgSO4 and concentrated in vacuo. The crude 
product was then purified by flash chromatography (silica gel, 90% Hexane: 10% EtOAc) to 
give 0.2301 g (69% yield) of compound 2-9 as a clear oil. 
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FTIR (neat) 3450, 2956, 2857, 1728, 1500, 1463, 1337, 1252, 1202, 1165, 1081, 1059, 1003; 1H 
NMR (500 MHz, Chloroform-d) δ 7.42 – 7.29 (m, 5H), 5.39 (d, J = 9.5 Hz, 1H), 5.16 (s, J = 1.7 
Hz, 2H), 4.48 (d, J = 9.5, 1.3 Hz, 1H), 3.97 (dd, J = 6.6, 1.3 Hz, 1H), 3.70 (s, 3H), 1.89 – 1.78 
(m, 1H), 1.02 – 0.88 (m, 15H), 0.03 (s, 3H), -0.08 (s, 3H); 13C NMR (126 MHz, cdcl3) δ 174.39, 
159.51, 137.93, 131.26, 131.22, 130.99, 130.87, 130.85, 79.42, 69.89, 58.48, 55.00, 35.68, 28.57, 
28.55, 28.31, 21.83, 20.79, -0.92, -1.63, -2.08; HRMS m/z calculated for C21H35O5N1Si1 
[M+Na]+ 432.2177, 432.2177 observed. 
 
[Compound 2-10] To a flame dried RBF containing 0.172 g (0.42 mmol) compound 2-9 was 
added 0.0150 g (0.13 mmol) Pd on C. The flask was put under positive pressure of H2 and stirred 
vigorously in 1.8 mL MeOH. After 6 hours, the reaction was diluted with MeOH (25 mL) and 
passed through a plug column of celite. The reaction was then concentrated in vacuo to give 
0.116 g (86% yield) compound 2-10 as a clear oil that was used without further purification. 
FTIR (neat) 2957, 2930, 2858, 1715, 1511, 1465, 1362, 1253, 1213, 1080 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 5.40 (d, J = 9.1 Hz, 1H), 4.45 (d, J = 9.1, 1.5 Hz, 1H), 4.01 (dd, J = 6.7, 
1.5 Hz, 1H), 3.71 (s, 3H), 1.90 – 1.77 (m, 1H), 0.95 – 0.89 (s, 15H), 0.08 (s, 3H), 0.01 (s, 3H); 
13C NMR (126 MHz, cdcl3) δ 179.54, 159.61, 79.67, 58.37, 55.17, 35.40, 28.56, 28.51, 28.26, 






[Compound 2-11] A stirred solution of 0.499 g (1.93 mmol) 8-(Boc-amino)octanoic acid and 
0.42 mL (3.86 mmol) of 4-methylmorpholine in 5 mL THF was brought to -10 °C. To the 
stirring solution 0.25 mL isobutyl chloroformate was added and maintained at -10 °C for 30 
minutes. The reaction was allowed to warm to 0 °C at which time 0.545 g (2.97 mmol) of the 
hydrochloride salt of β-hydroxyluecine in 3.5 mL of 1 M NaOH was added. The reaction was 
allowed to warm to room temperature overnight and stirred for 24 hours. The reaction was then 
diluted with 30 mL H2O, and washed with EtOAc (2x25 mL). The combined organic layers were 
then extracted with saturated NaHCO3 (3x25 mL). All aqueous layers were combined and 
acidified to pH=2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic 
layers were then dried with MgSO4 and concentrated in vacuo to give 0.696 g (88% yield) of 
compound 2-11 as a tan foaming oil that was carried forward without further purification. 
1H NMR (500 MHz, Methanol-d4) δ 4.69 (d, J = 2.5 Hz, 1H), 3.72 (dd, J = 9.1, 2.4 Hz, 1H), 3.03 
(t, J = 7.0 Hz, 3H), 2.35 – 2.28 (m, 2H), 1.72 – 1.61 (m, 3H), 1.44 (s, 11H), 1.36 (q, J = 6.7, 5.7 
Hz, 6H), 1.03 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cd3od) δ 
177.70, 175.84, 159.79, 81.03, 79.36, 57.21, 42.63, 38.20, 36.20, 33.76, 32.17, 31.43, 31.35, 




[Compound 2-12] To a stirring solution of 0.662 g (1.71 mmol) compound 2-11 with 0.661 g 
NaHCO3 (7.87 mmol) in 10 mL DMF was added 1.3 mL (15.8 mmol) Allyl Bromide in a 
dropwise fashion. The reaction was allowed to stir at room temperature overnight. After 20 hours 
the reaction was diluted with 30 mL H2O, and extracted with EtOAc (3x30 mL). The combined 
organic layers were then washed with brine (1x20 mL). The organic layer was then dried with 
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography 
(silica gel, 50% Hexane: 50% EtOAc) to give 0.4379 g (60% yield) of compound 2-12 as a clear 
oil. 
1H NMR (300 MHz, CDCl3) δ 6.75 (d, J=9.4 Hz, 1H), 5.78 (m, J=17.2, 10.4, 5.7 Hz, 1H), 5.20 -
5.11 (m, 2H), 4.69 (d, J=9.1, 2.1 Hz, 1H), 4.51 (d, J=5.3 Hz, 2H), 3.61 (dd, J=9.4, 1.8 Hz, 1H), 
2.96 (dd, J=5.9 Hz, 2H), 2.14 (t, J=7.3 Hz, 2H), 1.42 - 1.70 (m, 4H), 1.31 (s, 11H), 1.20 (br, 6H), 
0.89 (d, J=7.0 Hz, 3H), 0.79 (d, J=7.0 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 176.20, 174.15, 
158.72, 134.31, 121.25, 81.39, 80.04, 68.67, 56.97, 43.14, 39.02, 34.01, 33.75, 32.50, 31.45, 
31.15, 31.07, 30.63, 29.18, 28.09, 21.74, 21.56. Full characterization has been previously 
reported.1 
 
[Compound 2-13] The reaction was set up according to General Procedure: Amide Coupling 
(HATU). The crude product was then purified by flash chromatography (silica gel, 10% Hexane: 
90% EtOAc) to give 0.0631 g (77% yield) of compound 2-13 as a yellow oil. 
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FTIR (neat) 3296, 3079, 2931, 2858, 1748, 1650, 1544, 1439, 1374, 1177, 1061 cm-1; 1H NMR 
(500 MHz, Chloroform-d) δ 7.24 – 7.11 (m, 5H), 6.90 – 6.79 (m, 1H), 5.90 – 5.80 (m, 2H), 5.38 
– 5.30 (m, 2H), 5.30 – 5.15 (m, 2H), 5.00 – 4.88 (m, 3H), 4.58 (t, J = 11.3, 5.7, 2.7, 1.4 Hz, 2H), 
4.36 (ddd, J = 7.1, 6.1, 0.9 Hz, 1H), 4.28 (dd, J = 7.0, 1.1 Hz, 1H), 4.18 (dq, J = 7.7, 6.3, 5.4 Hz, 
1H), 3.32 (dd, J = 14.5, 3.6 Hz, 1H), 3.19 – 3.12 (m, 2H), 2.96 (ddd, J = 14.9, 9.6, 5.5 Hz, 1H), 
2.29 – 2.10 (m, 4H), 1.95 – 1.89 (m, 4H), 1.78 (dq, J = 13.3, 6.7 Hz, 1H), 1.57 (q, J = 7.5 Hz, 
2H), 1.45 – 1.33 (m, 2H), 1.31 – 1.12 (m, 5H), 0.96 (dd, J = 6.6, 0.9 Hz, 1H), 0.90 – 0.83 (m, 
6H);  13C NMR (126 MHz, cdcl3) δ 176.24, 174.01, 173.43, 173.22, 171.24, 139.24, 134.30, 
132.07, 132.02, 131.17, 130.99, 129.69, 122.22, 121.37, 89.59, 77.70, 73.44, 68.64, 55.38, 42.12, 
41.27, 40.44, 39.08, 37.55, 34.91, 33.84, 31.77, 31.53, 30.78, 29.22, 28.58, 25.30, 19.85. HRMS 
m/z calculated for C33H49O8N3 [M+Na]
+ 638.3412, 638.3385 observed.  
 
[Compound 2-14] The reaction was set up according to general procedure: Ring Closing 
Metathesis. The crude product was then purified by flash chromatography (silica gel, 10% 
Hexane: 90% EtOAc) to give 0.0519 g (57% yield) of compound 2-14 as a clear foaming oil. 
FTIR (neat) 3294, 2931, 2858, 1746, 1653, 1542, 1439, 1375, 1176, 1061 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 7.32 – 7.20 (m, 7H), 6.72 (t, J = 5.6 Hz, 1H), 6.15 (d, J = 6.3 Hz, 1H), 
5.54 – 5.49 (m, 2H), 5.37 (dd, J = 9.3, 3.8 Hz, 1H), 4.64 (dd, J = 13.1, 3.6 Hz, 1H), 4.49 – 4.42 
(m, 2H), 4.41 – 4.35 (m, 1H), 4.34 – 4.28 (m, 1H), 3.43 – 3.34 (m, 2H), 3.23 (ddd, J = 13.3, 8.7, 
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3.7 Hz, 1H), 3.07 (dd, J = 14.4, 9.3 Hz, 1H), 2.27 (t, J = 7.5 Hz, 3H), 2.17 – 2.09 (m, 1H), 2.00 
(s, 3H), 1.85 (dt, J = 13.3, 6.7 Hz, 1H), 1.70 – 1.50 (m, 4H), 1.39 – 1.20 (m, 4H), 0.94 (dd, J = 
14.7, 6.8 Hz, 6H); 13C NMR (126 MHz, cdcl3) δ 178.30, 175.42, 174.97, 174.03, 172.89, 140.38, 
133.18, 133.13, 132.20, 132.17, 131.95, 130.41, 130.07, 81.45, 64.73, 60.45, 57.22, 56.26, 42.60, 
41.37, 39.02, 38.19, 34.44, 33.19, 29.23, 26.70, 22.93, 22.53, 22.33, 21.87, 18.16.HRMS m/z 
calculated for C31H45O8N3 [M+Na]
+ 610.3099, 610.3068 observed. 
 
[Compound 2-15a] The reaction was set up according General Procedure: Amide Coupling 
(HATU). The crude product was then purified via flash chromatography (silica gel, 50% 
Hexane: 50% EtOAc) to give 0.197 g (64% yield) of compound 2-15a as a clear oil. 
FTIR (neat) 3306, 2931, 2858, 1747, 1699, 1650, 1536, 1440, 1372, 1259, 1156, 1156, 1058 cm-
1; 1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.16 (m, 5H), 6.87 – 6.79 (m, 1H), 6.55 (d, J = 
9.3 Hz, 1H), 5.89 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 5.36 – 5.21 (m, 3H), 5.01 (dd, J = 16.8, 6.5, 
3.2, 1.6 Hz, 2H), 4.84 (dd, J = 9.2, 2.2 Hz, 1H), 4.67 – 4.60 (m, 2H), 4.17 – 4.02 (m, 3H), 3.73 
(dd, J = 9.0, 2.2 Hz, 1H), 3.35 (dd, J = 14.4, 3.6 Hz, 1H), 3.27 – 3.13 (m, 2H), 3.06 – 2.99 (m, 
1H), 2.29 – 2.21 (m, 5H), 1.73 – 1.60 (m, 4H), 1.51 – 1.41 (m, 3H), 1.35 – 1.28 (m, 2H), 1.27 – 
1.20 (m, 3H), 1.02 (d, J = 6.7 Hz, 3H), 0.96 – 0.92 (d, 3H); 13C NMR (126 MHz, cdcl3) δ 176.21, 
174.17, 173.15, 171.41, 139.04, 134.35, 134.24, 132.06, 132.03, 131.00, 129.84, 129.49, 122.18, 
121.20, 77.72, 73.41, 68.61, 64.17, 57.04, 56.40, 41.99, 41.26, 40.44, 39.04, 37.82, 33.81, 31.43, 
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31.23, 28.96, 27.99, 21.61, 19.83, 17.12; HRMS m/z calculated for C34H51O9N3 [M+Na]
+ 
668.3518, 668.3484 observed. 
 
[Compound 2-16a] The reaction was set up according to general procedure: Ring Closing 
Metathesis. The crude product was then purified via flash chromatography (silica gel, 40% 
Hexane: 60% EtOAc) to give 0.108 g (59% yield) of compound 2-16a as a tan oil. 
FTIR (neat) 3305, 2931, 1700, 1652, 1537, 1454, 1372, 1260, 1175, 1059 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 7.32 – 7.19 (m, 5H), 6.67 (d, J = 5.7 Hz, 1H), 6.47 (dd, J = 13.1, 8.9 Hz, 
1H), 5.75 (d, J = 7.2 Hz, 1H), 5.56 (ddd, J = 16.9, 8.2, 6.2 Hz, 1H), 5.25 (dd, J = 9.3, 3.7 Hz, 
1H), 5.15 (dt, J = 15.5, 5.0 Hz, 1H), 4.74 (dd, J = 8.7, 2.0 Hz, 1H), 4.62 (dd, J = 13.3, 5.1 Hz, 
1H), 4.38 – 4.29 (m, 1H), 4.11 (dq, J = 11.4, 7.1 Hz, 2H), 3.74 (ddd, J = 8.9, 4.9, 1.9 Hz, 1H), 
3.48 – 3.37 (m, 1H), 3.32 (dt, J = 14.5, 4.7 Hz, 1H), 3.19 – 3.03 (m, 2H), 2.87 (t, J = 5.1 Hz, 
1H), 2.39 – 2.22 (m, 3H), 2.14 (dt, J = 14.2, 7.2 Hz, 0H), 1.78 – 1.69 (m, 1H), 1.68 – 1.60 (m, 
1H), 1.40 – 1.19 (m, 4H), 1.02 (dd, J = 16.3, 6.6 Hz, 3H), 0.97 – 0.90 (m, 3H); 13C NMR (126 
MHz, cdcl3) δ 176.77, 174.04, 173.32, 171.68, 159.20, 139.13, 131.03, 130.54, 130.26, 129.62, 
129.54, 129.44, 78.22, 66.68, 64.04, 63.07, 57.07, 56.57, 41.75, 40.31, 38.63, 36.84, 33.72, 
30.78, 30.45, 27.74, 26.60, 21.56, 19.82, 17.21, 16.86; HRMS m/z calculated for C32H47O9N3 




[Compound 2-15b] The reaction was set up according General Procedure: Amide Coupling 
(HATU). The crude product was then purified via flash chromatography (silica gel, 50% 
Hexane: 50% EtOAc) to give 0.164 g (68% yield) of compound 2-15b as a clear oil. 
FTIR (neat) 3311, 2930, 2857, 1745, 1651, 1537, 1455, 1372, 1202, 1059 cm-1; 1H NMR (500 
MHz, Chloroform-d) δ 7.31 – 7.16 (m, 5H), 6.81 (d, J = 6.8 Hz, 1H), 6.53 (d, J = 9.2 Hz, 1H), 
5.95 – 5.85 (m, 1H), 5.40 (td, J = 10.3, 9.1, 5.2 Hz, 2H), 5.35 – 5.09 (m, 5H), 4.85 (dd, J = 9.2, 
2.1 Hz, 1H), 4.69 – 4.61 (m, 2H), 4.29 – 4.21 (m, 1H), 4.14 – 4.02 (m, 3H), 3.74 (d, J = 9.0 Hz, 
1H), 3.28 (dd, J = 14.4, 4.1 Hz, 1H), 3.17 (dp, J = 19.3, 6.7 Hz, 2H), 3.07 (q, J = 7.0, 6.5 Hz, 
1H), 2.44 (t, J = 6.6 Hz, 2H), 2.26 (t, J = 7.6 Hz, 2H), 1.67 (dp, J = 30.0, 7.5, 7.0 Hz, 3H), 1.43 
(dt, J = 14.6, 8.5 Hz, 2H), 1.31 (qd, J = 8.9, 6.0, 5.0 Hz, 4H), 1.26 – 1.18 (m, 4H), 1.03 (d, J = 
6.6 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 176.21, 174.17, 173.15, 
171.41, 159.27, 139.04, 134.28, 132.08, 132.03, 131.97, 131.23, 131.00, 129.49, 122.18, 121.20, 
77.72, 73.41, 68.61, 64.17, 57.04, 56.40, 41.99, 41.26, 40.44, 39.04, 37.82, 33.81, 31.43, 31.23, 






[Compound 2-16b] The reaction was set up according to general procedure: Ring Closing 
Metathesis. The crude product was then purified via flash chromatography (silica gel, 40% 
Hexane: 60% EtOAc) to give 0.092 g (58% yield) of compound 2-16b as a tan oil. 
FTIR (neat) 3307, 2929, 2856, 1720, 1655, 1532, 1455, 1373, 1259, 1176, 1059 cm-1; 1H NMR 
(500 MHz, Chloroform-d) δ 7.35 – 7.21 (m, 7H), 7.21 – 7.17 (m, 3H), 6.27 (d, J = 9.0 Hz, 1H), 
5.75 – 5.66 (m, 1H), 5.59 (dt, J = 15.6, 5.5 Hz, 1H), 5.42 – 5.31 (m, 2H), 4.74 (dt, J = 8.4, 3.2 
Hz, 1H), 4.70 – 4.65 (m, 1H), 4.57 – 4.49 (m, 1H), 4.40 – 4.31 (m, 1H), 4.12 (dtdd, J = 10.6, 7.7, 
5.5, 3.0 Hz, 3H), 3.79 (dd, J = 9.0, 2.0 Hz, 1H), 3.30 – 3.14 (m, 6H), 2.32 (dq, J = 16.5, 9.9, 8.1 
Hz, 2H), 2.19 (ddd, J = 14.3, 8.3, 6.0 Hz, 1H), 1.72 (h, J = 6.6 Hz, 7H), 1.57 (dd, J = 14.4, 7.3 
Hz, 1H), 1.41 (dq, J = 18.6, 6.4, 5.6 Hz, 1H), 1.35 – 1.21 (m, 25H), 1.04 (d, J = 6.5, 4.7 Hz, 3H), 
0.99 – 0.93 (d, 3H); 13C NMR (126 MHz, cdcl3) δ 173.65, 171.45, 170.23, 168.41, 158.00, 
135.55, 129.88, 129.67, 128.46, 128.40, 128.01, 126.96, 126.93, 75.61, 64.70, 61.46, 54.52, 
54.50, 53.53, 39.07, 38.62, 37.63, 36.26, 34.94, 31.21, 30.98, 28.47, 26.15, 25.03, 19.19, 18.86, 
14.54; HRMS m/z calculated for C32H47O9N3 [M+Na]




 [Compound 2-17] The reaction was set up according to general procedure: Macrocycle 
Esterification. In an effort to confirm the necessity of purification prior to subsequent TBDMS 
deprotection crude material was carried forward. The crude material was then subjected to 
general procedure: TBDMS Deprotection. The crude product was then purified via flash 
chromatography (silica gel, 100% EtOAc) to give 8 mg (24% yield) of compound 2-17 as a tan 
oil over two steps. 
FTIR (neat) 3306, 2924, 2854, 1745, 1652, 1536, 1456, 1375, 1264, 1172, 1060 cm-1; 1H NMR 
(500 MHz, Chloroform-d) δ 7.38 – 7.24 (m, 8H), 7.19 (d, J = 11.8 Hz, 1H), 6.77 (dd, J = 13.0, 
6.1 Hz, 1H), 6.38 (q, J = 9.1, 8.2 Hz, 1H), 5.63 – 5.55 (m, 1H), 5.36 – 5.26 (m, 2H), 5.00 (dddd, 
J = 28.4, 13.7, 10.6, 6.0 Hz, 2H), 4.75 – 4.67 (m, 2H), 4.60 (d, J = 15.3 Hz, 1H), 4.49 (dq, J = 
12.8, 5.8, 3.5 Hz, 2H), 4.36 (d, J = 12.8 Hz, 1H), 4.25 – 4.12 (m, 2H), 3.74 (tt, J = 9.2, 4.7 Hz, 
5H), 3.53 – 3.37 (m, 2H), 3.22 (ddt, J = 14.4, 9.5, 4.3 Hz, 2H), 3.07 (tdd, J = 14.1, 10.4, 4.7 Hz, 
1H), 2.41 – 2.26 (m, 4H), 2.11 – 1.95 (m, 7H), 1.90 – 1.71 (m, 5H), 1.47 – 1.20 (m, 14H), 1.17 – 
1.10 (m, 3H), 1.08 – 0.85 (m, 10H). 13C NMR (126 MHz, cdcl3) δ 177.81, 174.66, 174.00, 
173.07, 173.05, 172.11, 159.63, 139.75, 132.25, 132.17, 131.09, 131.07, 129.53, 128.36, 128.34, 
78.95, 67.40, 59.60, 59.57, 55.28, 55.23, 54.61, 41.67, 40.51, 37.98, 37.24, 33.60, 32.37, 32.34, 
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30.88, 30.86, 29.61, 29.45, 26.69, 25.30, 22.11, 21.63, 21.43, 21.02. HRMS m/z calculated for 
C39H58O12N4 [M+Na]
+  775.4124,775.4089 observed. 
 
[Compound 2-18a] The reaction was set up according to general procedure: Macrocycle 
Esterification. The crude product was then purified via flash chromatography (silica gel, 60% 
Hexane: 40% EtOAc) to give 0.0555 g (50% yield) of compound 2-18a as a clear foaming oil. 
Efforts were not made to fully characterize intermediate 2-18a as it was deemed unnecessary to 
purify material prior to subsequent TBDMS deprotection. 
 
[Compound 2-19a] The reaction was set up according to general procedure: TBDMS 
Deprotection. The crude product was then purified via flash chromatography (silica gel, 70% 
Hexane: 30% EtOAc) to give 0.0113 g (58% yield) of compound 2-19a as a tan oil. 
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FTIR (neat) 3308, 2930, 1703, 1652, 1529, 1455, 1372, 1260, 1169, 1114, 1058 cm-1; 1H NMR 
(500 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 10H), 6.85 – 6.79 (m, 1H), 6.28 (d, J = 8.4 Hz, 1H), 
6.02 (d, J = 7.1 Hz, 1H), 5.56 (d, J = 8.8 Hz, 2H), 5.49 – 5.41 (m, 0H), 5.39 – 5.34 (m, 1H), 5.10 
(dd, J = 10.1, 3.3 Hz, 1H), 5.04 – 5.00 (m, 2H), 4.81 (dd, J = 12.0, 7.4 Hz, 1H), 4.73 (d, J = 8.5 
Hz, 1H), 4.52 (dd, J = 13.9, 4.7 Hz, 1H), 4.44 (ddd, J = 9.7, 5.1, 1.7 Hz, 1H), 4.38 (q, J = 6.1 Hz, 
1H), 4.22 (d, J = 13.3 Hz, 1H), 4.16 – 4.04 (m, 4H), 3.74 – 3.67 (m, 6H), 3.24 (dd, J = 14.3, 3.3 
Hz, 1H), 3.18 – 3.06 (m, 1H), 2.38 – 2.21 (m, 4H), 2.12 (td, J = 9.0, 8.4, 4.7 Hz, 1H), 1.94 (ddt, J 
= 21.4, 8.2, 6.7 Hz, 1H), 1.80 (ddd, J = 13.3, 8.6, 6.5 Hz, 1H), 1.75 – 1.67 (m, 1H), 1.65 – 1.56 
(m, 1H), 1.53 – 1.43 (m, 1H), 1.41 – 1.31 (m, 6H), 1.29 – 1.20 (m, 7H), 1.12 – 1.04 (m, 4H), 
1.04 – 0.87 (m, 14H); 13C NMR (126 MHz, cdcl3) δ 177.34, 174.52, 174.05, 173.11, 171.91, 
159.64, 159.06, 139.47, 132.26, 132.21, 132.05, 131.04, 130.94, 129.48, 129.16, 80.51, 78.37, 
67.55, 63.80, 63.03, 59.53, 56.29, 55.34, 41.69, 40.45, 38.13, 37.28, 33.53, 32.27, 30.66, 29.95, 
27.10, 25.82, 23.69, 22.02, 21.62, 20.95, 17.24, 16.85, 16.05; HRMS m/z calculated for 
C40H60O13N4 [M+Na]
+ 827.4049, 827.3993 observed. 
 
[Compound 2-18b] The reaction was set up according to general procedure: Macrocycle 
Esterification. The crude product was then purified via flash chromatography (silica gel, 70% 
Hexane: 30% EtOAc) to give 0.0555 g (63% yield) of compound 2-18a as a clear foaming oil. 
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Efforts were not made to fully characterize intermediate 2-18b as it was deemed unnecessary to 
purify material prior to subsequent TBDMS deprotection. 
 
[Compound 2-19b] The reaction was set up according to general procedure: TBDMS 
Deprotection. The crude product was then purified via flash chromatography (silica gel, 70% 
Hexane: 30% EtOAc) to give 11 mg (64% yield) of compound 2-19a as a tan oil. 
FTIR (neat) 3324, 2933, 1725, 1658, 1534, 1455, 1372, 1265, 1175, 1115, 1060 cm-1; 1H NMR 
(500 MHz, Chloroform-d) δ 7.32 – 7.14 (m, 6H), 6.27 (d, J = 9.4 Hz, 2H), 6.18 (s, 1H), 5.60 (dp, 
J = 27.5, 7.3, 6.4 Hz, 2H), 5.46 – 5.37 (m, 1H), 5.29 (d, J = 7.5 Hz, 1H), 5.06 (ddd, J = 11.2, 9.2, 
1.9 Hz, 1H), 4.92 – 4.77 (m, 1H), 4.75 – 4.65 (m, 1H), 4.46 – 4.37 (m, 2H), 4.34 – 4.28 (m, 2H), 
4.12 (dq, J = 10.5, 7.1 Hz, 4H), 3.75 – 3.63 (m, 5H), 3.62 (d, J = 8.8 Hz, 1H), 3.28 – 3.17 (m, 
4H), 3.16 (dt, J = 14.4, 4.3 Hz, 3H), 2.55 (d, J = 14.7 Hz, 2H), 2.43 (q, J = 7.1 Hz, 1H), 2.32 (s, 
2H), 2.20 (ddd, J = 14.5, 8.5, 6.0 Hz, 1H), 2.05 (s, 2H), 1.95 (dp, J = 9.2, 6.7 Hz, 1H), 1.75 (s, 
7H), 1.58 – 1.51 (m, 1H), 1.42 (dd, J = 13.7, 7.0 Hz, 2H), 1.27 (ddd, J = 9.3, 6.1, 2.5 Hz, 13H), 
1.11 – 0.96 (m, 8H), 0.93 (q, J = 6.0, 5.5 Hz, 10H); 13C NMR (126 MHz, cdcl3) δ 176.67, 
174.26, 174.01, 172.77, 171.06, 159.79, 159.02, 138.31, 132.32, 132.29, 131.34, 131.32, 131.00, 
130.29, 129.56, 81.19, 78.03, 68.27, 64.11, 63.05, 59.33, 55.54, 55.18, 41.81, 40.33, 38.65, 
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37.45, 33.31, 32.19, 31.04, 30.88, 28.73, 27.47, 23.70, 21.58, 20.98, 18.06, 17.18, 16.99, 16.85; 
HRMS m/z calculated for C40H60O13N4 [M+Na]
+ 827.4049, 827.4000 observed. 
 
[Compound 2-20] A stirred solution 0.5024 g (2.74 mmol) of the hydrochloride salt of β-
hydroxy leucine with 0.6880 g (8.16 mmol) NaHCO3 in 10 mL H2O and 10 mL THF was 
brought to 0 °C. To this stirring solution was added 2.4 mL (17.2 mmol) 2,2,2-
trichloroethoxycarbonyl chloride in three 0.8 mL portions over the next 30 minutes. Reaction 
was allowed to stir and reach room temperature overnight. After 24 hours, the reaction was 
diluted with H2O (30 mL), and then washed with EtOAc (2x30 mL). The organic layer was then 
back extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then 
acidified to pH = 2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic 
layers were then dried with MgSO4 and concentrated in vacuo to give 0.6955 g (79% yield) 
compound 2-20 as a yellow foaming oil that was used without further purification. 
1H NMR (500 MHz, Chloroform-d) δ 6.22 (d, J = 9.5 Hz, 1H), 4.83 (d, J = 12.0 Hz, 1H), 4.69 
(d, J = 12.0 Hz, 1H), 4.59 (dd, J = 9.6, 1.9 Hz, 1H), 3.85 (dd, J = 9.4, 1.9 Hz, 1H), 1.79 (m, J = 
9.4, 6.6 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 





[Compound 2-21] The reaction was set up according to General Procedure: Lactone 
Formation. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.4222 g (71% yield) of compound 2-21 as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 5.91 (d, J = 9.3 Hz, 1H), 5.53 (d, J = 8.2, 6.0, 2.1 Hz, 1H), 
4.99 – 4.91 (d, 1H), 4.88 – 4.81 (d, 1H), 4.34 – 4.25 (dd, 1H), 1.93 (m, 1H), 1.15 – 1.04 (d, 3H), 
0.96 (d, J = 30.4, 6.8, 2.1 Hz, 3H). 13C NMR (126 MHz, cdcl3) δ 171.17, 156.45, 85.17, 77.65, 
77.49, 62.26, 31.41, 21.11, 19.91. Full characterization of compound 2-21 was not obtained as 
this pathway was deemed unsuitable for future use. 
 
[Compound 2-22] In a flame dried flask was added 0.222 g (0.73 mmol) compound 2-21 which 
was then dissolved in 9.0 mL (94.9 mmol) acetic anhydride. This solution was then added via 
syringe to a flask charged with 0.8560 g (13.1 mmol) freshly activated Zinc. To this flask was 
added 0.18 mL (1.31 mmol) triethylamine. This reaction mixture was sonicated at 0°C for four 
hours after which the reaction contents were diluted with methanol (50 mL) and filtered to 
remove solid. The filtrate was then concentrated in vacuo. The crude product was then purified 
by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.0359 g (29% yield) of 
compound 2-22 as a pale yellow oil. 
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1H NMR (300 MHz, Chloroform-d) δ 6.29 (d, J = 8.8 Hz, 1H), 5.71 (d, J = 8.8, 5.9 Hz, 1H), 4.26 
(dd, J = 10.3, 5.9 Hz, 1H), 2.07 (s, 3H), 1.94 – 1.81 (m, 1H), 1.08 (d, J = 6.5 Hz, 3H), 0.88 (d, 
3H). Full characterization of compound 2-22 was not obtained as this pathway was deemed 
unsuitable for future use. 
 
[Compound 2-23] A stirred solution 0.3074 g (2.63 mmol) of the hydrochloride salt of β-
hydroxyluecine with 0.4200 g (4.90 mmol) NaHCO3 in 5.8 mL H2O was brought to 0 °C. To this 
stirring solution was added 0.5836 g (2.67 mmol) Boc2O dissolved in 2.2 mL THF. The reaction 
was allowed to stir and reach room temperature overnight. After 18 hours, the reaction was 
diluted with H2O (30 mL), and then washed with EtOAc (2x30 mL). The organic layer was then 
back extracted with saturated NaHCO3 (3x25 mL). The combined aqueous layers were then 
acidified to pH = 2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic 
layers were then dried with MgSO4 and concentrated in vacuo to give 0.3613 g (87% yield) 
compound 2-23 as a white foaming oil that was used without further purification. 
1H NMR (500 MHz, Chloroform-d) δ 5.68 (d, J = 9.4 Hz, 1H), 4.44 (d, J = 9.3 Hz, 1H), 3.78 – 
3.72 (dd, 1H), 1.78 – 1.71 (m, 1H), 1.43 (s, 9H), 1.01 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 14.2, 6.7 
Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 178.67, 159.21, 82.80, 82.79, 58.67, 33.80, 




[Compound 2-24] The reaction was set up according to General Procedure: Lactone 
Formation. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.3739 g (77% yield) of compound 2-24 as a white solid. 
1H NMR (300 MHz, Chloroform-d) δ 5.48 (dd, J = 9.3, 5.7 Hz, 1H), 5.41 (d, 1H), 4.22 (dd, J = 
10.4, 5.7 Hz, 1H), 2.03 – 1.84 (m, 1H), 1.45 (s, 9H), 1.08 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.6 Hz, 
3H); 13C NMR (151 MHz, cdcl3) δ 169.80, 154.43, 82.85, 81.13, 59.18, 28.64, 28.64, 28.10, 
28.10, 18.41, 17.05. Full characterization of compound 2-24 was not obtained as this pathway 
was deemed unsuitable for future use. 
 
[Compound 2-25] The reaction was set up according to General Procedure: Lactone 
Formation. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.3412 g (75% yield) of compound 2-25 as a white solid. 
1H NMR (300 MHz, Chloroform-d) δ 5.50 (d, J = 5.8 Hz, 2H), 4.25 (dd, J = 10.2, 5.6 Hz, 1H), 
3.74 (s, 3H), 1.91 (dp, J = 10.3, 6.6 Hz, 1H), 1.09 (d, J = 6.5, 0.9 Hz, 3H), 0.92 (d, J = 6.6, 0.9 
Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 169.70, 156.08, 82.82, 59.53, 53.05, 28.60, 
18.46, 17.26. Full characterization of compound 2-25 was not obtained as this pathway was 




[Compound 2-26] A stirred solution 0.3500 g (1.90 mmol) of the hydrochloride salt of β-
hydroxyleucine with 0.4789 g (5.70 mmol) NaHCO3 in 6 mL H2O was brought to 0 °C. To this 
stirring solution was added 6 mL THF followed by 1.1 mL (11.4 mmol) ethyl chloroformate in 
three 0.35 mL portions over the next 30 minutes. The reaction was allowed to stir and reach 
room temperature overnight. After 20 hours, the reaction was diluted with H2O (30 mL), and 
then washed with EtOAc (2x30 mL). The organic layer was then back extracted with saturated 
NaHCO3 (3x25 mL). The combined aqueous layers were then acidified to pH = 2 with 1 M HCl 
and extracted with EtOAc (3x30 mL). The combined organic layers were then dried with MgSO4 
and concentrated in vacuo to give 0.0.3586 g (86% yield) compound 2-26 as a clear foaming oil 
that was used without further purification. 
1H NMR (300 MHz, Chloroform-d) δ 6.04 (d, J = 9.4 Hz, 1H), 4.71 – 4.60 (d, 1H), 4.30 – 4.21 
(q, 2H), 3.90 (dd, J = 9.5 Hz, 1H), 1.89 (m, 1H), 1.37 (t, J = 7.1 Hz, 3H), 1.17 – 1.11 (d, 3H), 
1.04 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 175.71, 157.29, 77.42, 61.47, 
56.13, 30.64, 19.13, 18.78, 14.35. Full characterization of compound 2-26 was not obtained as 




[Compound 2-27] The reaction was set up according to General Procedure: Lactone 
Formation. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.2545 g (77% yield) of compound 2-27 as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 5.65 (d, J = 8.5 Hz, 1H), 5.51 (d, J = 9.4, 5.9 Hz, 1H), 4.24 
(dd, J = 10.3, 5.9 Hz, 1H), 4.20 – 4.12 (q, 2H), 1.92 (m, J = 10.3, 6.7 Hz, 1H), 1.30 – 1.23 (t, 
3H), 1.08 (d, J = 6.5 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 
169.48, 155.47, 82.66, 62.03, 59.42, 28.63, 18.39, 17.19, 14.38. Full characterization of 
compound 2-27 was not obtained as this pathway was deemed unsuitable for future use. 
 
[Compound 2-28] The reaction was set up according to General Procedure: Lactone 
Formation. The crude product was then purified by flash chromatography (silica gel, 80% 
Hexane: 20% EtOAc) to give 0.2991 g (64% yield) of compound 2-28 as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.29 (m, 5H), 5.86 (d, J = 8.7 Hz, 1H), 5.45 (dd, J = 
8.8, 5.8 Hz, 1H), 5.12 (s, 2H), 4.83 (m, J = 6.3 Hz, 1H), 1.42 (d, J = 6.1 Hz, 3H). 13C NMR (126 
MHz, cdcl3) δ 171.63, 158.13, 138.21, 131.31, 131.31, 131.31, 130.90, 130.81, 77.52, 70.49, 
63.01, 17.60. Full characterization of compound 2-28 was not obtained as this pathway was 





The reaction was set up according to General Procedure: Lactone Formation. The crude product 
was then purified by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.2983 
g (64% yield) of compound 2-29 as a clear oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.46 – 7.38 (m, 3H), 7.28 (m, J = 6.1 Hz, 2H), 5.81 – 5.72 
(m, 2H), 4.86 (d, J = 9.4 Hz, 1H), 1.33 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 171.92, 156.73, 
135.80, 131.68, 131.61, 131.57, 128.43, 83.76, 80.35, 64.95, 30.98, 30.90, 30.67, 29.94. Full 




The reaction was set up according to General Procedure: Lactone Formation. The crude product 
was then purified by flash chromatography (silica gel, 80% Hexane: 20% EtOAc) to give 0.1144 
g (55% yield) of compound 2-30 as a white solid.  
1H NMR (500 MHz, Chloroform-d) δ 5.51 (d, J = 8.3 Hz, 1H), 5.42 (dd, J = 8.7, 5.9 Hz, 1H), 
4.85 (dq, J = 6.2 Hz, 1H), 1.45 (s, 12H). 13C NMR (151 MHz, Chloroform-d) δ 169.46, 154.58, 
81.10, 74.97, 60.00, 28.09, 14.86. Full characterization of compound 2-30 was not obtained as 
this pathway was deemed unsuitable for future use. 
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Chapter Three: Simplified Analogs 
Conclusions and Future Directions 
3.1 First Generation Synthesis 
 
 
Figure 3.1 – WU-07047 & FR900359 
 This project began with the successful synthesis of analog WU-07047 (Figure 3.1), also 
highlighted in Figure 1.4. This analog was then screened in a receptor-assisted GTPγS 
nucleotide exchange assay to determine its inhibitory activity in comparison to the natural 
product FR.1-3 In this assay the uptake of GTP was observed using GTPγS, a γ-phosphate 
radiolabeled with 35S. As an inactive G protein is bound to GDP (Figure 1.1), observing an 
uptake in GTP is indicative of the activation of this cell signaling pathway. We hoped to observe 
less of an uptake of GTP, indicating the successful binding and subsequent inactivation of this 
cell signaling pathway. When compared to the commercially available compound UBO-QIC, 
now referred to as FR900359 (Figure 3.1) there are two noteworthy observations regarding WU-
07047. First, WU retained selectivity towards only one G protein and successfully inhibited 
nucleotide exchange on Gαq in a concentration dependent manner. Second, while WU was able 
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to inhibit nucleotide exchange with similar efficacy as FR (up to 40% inhibition of nucleotide 
exchange) it was much less potent (Figure 3.2).4  
 
Figure 3.2 – Receptor-assisted GTPγS Nucleotide Exchange Assay4 
We believe this loss is due to the simplification of the top and bottom bridges to alkyl 
chains. Efforts were first made to install an intramolecular hydrogen bond found in the natural 
product to the simplified analog. 
3.2 Top Bridge Amide Bond Installation 
In the first attempt to return biological activity to a simplified analog, Dr. Derek Rensing 
chose to install an amide bond within the simplified alkyl chain of the top bridge in WU-07047.5 
This decision was made based on an intramolecular hydrogen bond that appears to be important 
in the crystal structure of YM bound to its active site in Gαq. This hydrogen bond donor is 
highlighted red in both FR and the new, simplified analog WU-09060 (Figure 3.3). The intent 
was to stabilize the bound conformation of the analog by returning this intramolecular hydrogen 




Figure 3.3 – FR900359 & WU-09060 
 Significant challenges were faced when assembling this analog, inevitably leading to the 
analog WU-09060 in only a 1.8% overall yield, with a longest linear reaction sequence of 10 
steps. When tested for its ability to inhibit exchange of GDP for GTP on Gαq the analog installed 
with the intramolecular hydrogen bond proved to be worse than the first simplified analog WU-
07047 (Figure 3.5). Due to the difficulties associated with the synthesis of WU-09060 and the 
loss of potency and efficacy in the biological assay, this analog is no longer being pursued. The 
observation that a change within the top bridge of the simplified analogs did not lead to a 
significant change in biology is consistent with the suggestion that the top bridge of the molecule 
may not play a significant role in binding. As mentioned in Section 1.2, this portion of the 
molecule appears to reside outside of the active site in the natural product – receptor complexes 
forwarded to date. This knowledge, in addition to information currently available in the 
literature, has led to the decision to install the “bottom bridge” of the macrocycle (discussed in 




3.3 Inhibition of Vasoconstriction by YM & WU 
In addition to the biological studies underway in our collaboration with the Blumer lab 
studying G protein signaling and its relationship to uveal melanoma, our collaborators in the 
Osei-Owusu lab are exploring the use of our simplified analogs in connection with the role of 
Gαq/11 in vasoconstriction. 6 Alone these lines, calcium influx through voltage-gated L-type 
calcium channels (LTCC) and receptor-operated calcium channels are critical for 
vasoconstriction, and it appears that Gαq/11 plays a critical role in regulating these cell signaling 
events. As such, efforts have been made to determine the ability of Gαq/11 inhibitors to block 
the LTCC. This has led to a unique observation. Both YM and WU exhibit an inhibitory effect 
on calcium influx by partially targeting the LTCC itself, in addition to Gαq/11, thereby blocking 
vasoconstriction. This is in contrast to FR, which blocks vasoconstriction by only targeting 
Gαq/11, with no off-target binding at the LTCC. Efforts to synthesize new analogs to probe this 
difference between activity are currently underway and will be discussed in Section 3.6. 
3.4 Alternative Binding Mode of WU 
The observation that YM and WU partially block vasoconstriction through targeting the 
LTCC led to a molecular modeling study comparing the critical residues within the hydrophobic 
pocket of Gαq/11 to that of the LTCC. It was found that there was significant homology between 
the two receptors, potentially accounting for YM and WU’s ability to block vasoconstriction by 
binding to the LTCC. Interestingly, while both YM and WU bind to the LTCC, molecular 
modeling suggests that the two molecules bind the receptor with distinct binding motifs (Figure 




Figure 3.4 – WU-07047 & YM-254890 Binding6 
 In the case of YM, the phenyl ring of the phenylacetic acid (DPla6) binds in a 
hydrophobic pocket near amino acid residue Y168. In comparison, the bound WU analog places 
the phenyl ring towards amino acid residue F203, and the isopropyl group of the β-hydroxy 
leucine tail is oriented towards Y168. These observations have led to the projection of a variety 
of analogs to probe this unique binding motif. Is it possible to exploit the binding motif displayed 
above to develop an analog that is selective towards the LTCC receptor in the same fashion that 
FR is selective towards only Gαq? These analogs will be discussed further detail in Section 3.6. 
3.5 Methyl Carbamate Protecting Group 
The use of a methyl chloroformate as a replacement for the acetate group on the β-
hydroxy leucine tail was chosen in the hopes that it would be biologically tolerated thereby 
eliminating the need exchange protecting groups in the final steps of the synthesis. As previously 
mentioned, the use of an acetyl protecting group on an amino acid derivative is not compatible 
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with an esterification reaction of the acid and hence cannot be used to add the β-hydroxy leucine 
side chain. The hypothesis that the methyl carbamate would be tolerated was based upon the 
observation that one of the two differences between YM and FR occurs at this site. The FR 
natural product has a propionate group at this position, and a variety of analogs of FR have been 
isolated with groups larger than a propionate appended to the amine in the β-hydroxy leucine 
side chain.7  
 
Figure 3.5 – Comparison of FR to WU Analogs 
Fortunately, not only did the use of a methoxycarbamate protecting group result in an 
improvement of overall yields, but it also improved the efficacy and potency of the analog 
relative to the first simplified analog WU-07047. This new analog, Compound 2-17, is labeled 
WU_06047 in Figure 3.5.  In this case, the efficacy of the simplified analogs was compared to 
that of FR using an agonist-induced Ca2+ flux assay.8 In this assay HEK2923 cells were 
transfected with a Twitch 2B Ca2+ Fret reporter. The cells were then treated with FR, an FR 
analog, or a vehicle for three hours, and then stimulated with the Gq-coupled GPCR agonist 
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carbachol. The recorded changes in Twitch 2B fluorescence and FRET are reported in Figure 
3.5. While the analog WU_06047 is a step in the right direction, we are still far from the efficacy 
found in the natural product FR.  
3.6 Simplified Analogs from Molecular Modeling 
Based upon some of the observations discussed in Section 3.4, there are a handful of 
analogs of interest that are currently in development. There is significant interest in probing the 
hydrophobic pocket the phenyl ring within the right-hand portion of the molecules (highlighted 
red in Figure 3.6). Analogs in development will have hydroxy or methoxy substituents in either 
the ortho, meta, or para positions.  
 
Figure 3.6 – Simplified Analogs from Molecular Modeling 
Due to the unique inverted binding mode to the LTCC predicted for analog WU-07047, 
an analog containing a phenyl group in place of an isopropyl group of the β-hydroxyleucine tail 
is being synthesized by Dr. Ruby Krueger in our lab. Dr. Krueger has been able to rapidly 
assemble the core ring scaffold and is currently at the final esterification reaction necessary to 
add the β-hydroxy leucine side-chain. Her ability to rapidly reach this point in the synthesis 
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within several weeks of joining our lab is further evidence of the success and reproducibility of 
our second-generation synthesis.  
3.7 Simplified Analogs to Improve Efficacy 
The second-generation synthesis has given us rapid access to analogs to probe distinct 
portions of the simplified analogs. Two such analogs that may significantly improve activity with 
few changes in our synthetic strategy are outlined in Figure 3.7. According to current SAR 
studies, the exchange of the NMe-amide labeled 1 to an amide results in a 670-fold loss in 
potency. Similarly, the exchange of the NMe-amide labeled 2 resulted in a nearly 500-fold loss 
in potency.9 
 
Figure 3.7 – Recommended Analogs Based on SAR 
 The installation of the NMe-amides within the structure should in theory require only one 
additional step to install each NMe-amine (Figure 3.8). The methylation of the amine within the 
“top bridge” labeled 1 can be synthesized by treating Boc-8-aminocaprylic acid with methyl 
iodide and sodium hydride. These conditions will mimic the methylation conditions used in the 
synthesis of NMe-OMe-Thr in our central building block (Scheme 3.1).9,10 The installation of 
the NMe-amide within the “bottom bridge” labeled 2 could be readily synthesized from 
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Compound 2-11. In our second-generation synthesis Compound 2-11 was protected with an 
allyl ester (Scheme 2.3). In this case, it may be plausible to use standard coupling conditions to 
couple the carboxylic acid with an N-allylmethylamine. Upon synthesis of these two molecules, 
the synthetic route to the final product would not vary from our second-generation synthesis. 
 
Figure 3.8 – N-Methyl Synthetic Strategy 
3.8 Conclusions from Simplified Analogs 
 
Figure 3.9 – Second Generation Synthesis 
 The use of our second-generation synthesis has played a key role in the development and 
scaling of new analogs. The key step, the addition of the β-hydroxy leucine to the macrocycle 
last (Figure 3.9), provided the first evidence that this esterification can be accomplished in the 
final stage of a synthesis. A key component of this second-generation synthesis is the use of a 
methyl carbamate protecting group in place of the acetyl group located on the β-hydroxyleucine 
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tail in the natural product. At present, this synthetic route has produced three different analogs, 
and is still in use for the rapid synthesis of chemical probes (some in as little as 2-3 weeks). This 
overall strategy will continue to be employed for the development of all new analogs to probe the 
GPCR many of which were discussed above. With the second-generation strategy in place, we 
have turned our attention to returning efficacy and potency to our simplified analogs and the 
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Chapter Four: Returning Activity through 
Installation of the Bottom Bridge 
4.1 A New Retrosynthetic Analysis 
As more information has become available, the X-ray crystal driven hypothesis that only 
the left- and right-hand portions of the natural product that make direct contact with Gαq are 
necessary for the activity of the molecule has been shown to be incorrect. This has been 
confirmed through the synthesis of our simplified analogs that retain selectivity towards Gαq, but 
do not have either the same potency or efficacy as the natural product. This knowledge combined 
with the work of others suggests the importance of the “bottom bridge”.1,2 In these structure 
activity studies, changes within the bottom bridge have had a significant impact on the potency 
and efficacy of the analog. For example, exchanging the NMe-OMe-Thr for a threonine within 
central building block (Figure 4.1) resulted in nearly a 500-fold loss in potency. Whether 
through direct contact with the active site, or through conformational constraint, it appears that 
incorporation of an intact portion of the macrocycle (stretching from DhAla to β-hydroxyleucine) 
will be necessary to improve binding the activity of the analogs being scaled. 
 




From the lessons learned from our second-generation synthesis discussed in Chapter 2, 
the plan for construction of a more functionalized analog called for the addition of the β-hydroxy 
leucine tail last, and a ring closing metathesis strategy to tie together the macrocycle (Figure 
4.1). In the retrosynthetic analysis, following removal of the β- hydroxy leucine tail, the 
synthesis breaks down to the construction and subsequent assembly of three major building 
blocks. The right-hand portion is a coupled product of N-allylamine and a phenylacetic acid 
derivative. The central portion is a known building block that is a dipeptide made from a 
demethylated threonine and an N-acylated threonine.1 The left-hand portion of our molecule is a 
coupled product of a β-hydroxy leucine to a carboxylic acid derivative containing a terminal 
alkene. The plan called for assembly of these three molecules required standard coupling or 
esterification procedures, with the formation of the macrocycle using a ring closing metathesis 
reaction. This convergent route will give us rapid access to multiple analogs. With that backdrop, 
we begin with the reported synthesis of the bottom bridge and the challenges associated with its 
assembly. 
4.2 Synthesis of the Bottom Bridge 
 
Scheme 4.1 – Central Building Block Synthesis 
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The synthesis of the central building block was repeated following current literature 
protocol.1,2 The synthesis began with Boc protected threonine that was treated with an excess of 
sodium hydride (5 eq.) and methyl iodide (10 eq.). This afforded compound 3-3 as an 
inseparable mixture of NMe-OMe-Thr and β-elimination product in a ratio between [3-1] and [4-
1] determined by proton NMR integration. This material was purified following coupling to 
previously synthesized compound 3-1. In our hands, this product could be synthesized in a 27% 
isolated yield over three steps (Scheme 4.1). While the structure of the product was confirmed, it 
could not be readily carried forward in subsequent reactions to assemble the larger acyclic 
structure. Yet another β-elimination plagued synthetic transformations using this building block 
as starting material (Figure 4.2). For example, while compound 3-4 can be stored below room 
temperature to significantly slow the β-elimination, this decomposition occurs during 
purification, and in the presence of base in subsequent reactions.  
 
Figure 4.2 – β-Elimination Decomposition Products 
Despite the evidence of this decomposition pathway efforts were made to push forward in 
the synthesis. While we were able to handle these molecules gently enough to minimize this 
decomposition as evidence of the synthesis of compound 3-13 in 66% yield across two steps 
(Scheme 3.2). As we carried compound 3-13 forward to the subsequent Boc deprotection and 




Scheme 4.2 – Central Building Block Mitsunobu Reaction 
 
Figure 4.3 – Further Evidence of β-Elimination  
At this point it had become clear that the β-elimination needed to be addressed 
immediately because similar reactions will occur in all subsequent steps of this reaction sequence 
prior to the macrocyclization. One simple option that we hoped would slow this β-elimination, 
was to change the N-acetyl protecting group so that the nitrogen would not be as electron-
withdrawing, a change that would decrease the acidity of the α-proton involved in the 
elimination. Given our prior experience with the second-generation synthesis, we chose to 
protect this amine with a methyl carbamate, at the time hoping this change in the final analog 
would once again be tolerated biologically. This will allow us to avoid an exchange of protecting 




4.3 Avoiding the β-Elimination of the Bottom Bridge 
 
Scheme 4.3 – Modified Central Building Block Synthesis 
The synthesis of the modified central building block (the “bottom bridge” in the natural 
product) began in a similar fashion as reported above (Scheme 4.3).1,2 The first modified amino 
acid required for the central building block was synthesized from the commercially available 
benzyl ester of the threonine oxalate salt. This substrate was chosen due to difficulties isolating 
the methyl carbamate protected acid of threonine itself from the aqueous layer following work 
up. The methyl carbamate protected compound 3-2 was isolated in an 84% yield underwent the 
subsequent esterification reaction with the previously synthesized NMe-OMe-Thr (compound 3-
3), using catalytic DMAP and no additional stoichiometric base in an effort to reduce the amount 
of β-elimination side product generated. This reaction afforded a 75% yield of compound 3-5. 
When compared to the overall yield across the same steps containing the N-acyl amine, there 
was an improvement in yield observed from 27% to 42% yield over three steps, with less 
evidence of elimination product. It appears that the use of the modified protecting group strategy 




4.4 Synthesis of the Right-Hand Building Block 
 
Scheme 4.4 – Right-Hand Piece Synthesis 
The synthesis of the right-hand building block was accomplished through a standard 
amide coupling procedure with HATU and DIPEA (Scheme 4.4). In this case, the 
thermodynamic amide product, compound 3-6, was isolated in an 82% yield. A slight excess of 
our phenylacetic acid derivative (1.2 eq.) was used, as any uncoupled material would be lost in 
aqueous work up. With the right-hand building block in hand we could now turn our attention to 
the final piece of the macrocycle, the left-hand building block. 
4.5 Synthesis of the Left-Hand Building Block 
  
Scheme 4.5 – Left-Hand Building Block Synthesis 
They synthesis of the left-hand building block began in a similar fashion to our previous 
synthesis (Scheme 4.5). To this end, we were able to activate the carboxylic acid derivative as a 
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mixed anhydride. Upon treatment of the mixed anhydride with β-hydroxy leucine in 1 M NaOH, 
compound 3-7 was generated in an 81% yield. The intent was to carry this material forward to 
the coupling of the NMe-threonine within the central building block. However, this coupling 
reaction resulted in poor yields of the desired amide product.  
 
Figure 4.4 – Evidence of Esterification 
In our second-generation synthesis, it was possible to isolate the thermodynamic amide 
product in the presence of a free hydroxyl group (Scheme 2.4). In this case however, it appears 
that the acylation of the methyl amine is much too slow. As evidence, the major product isolated 
shown in Figure 4.4 was clearly evidence of the β-elimination we have seen time and time again. 
For this β-elimination reaction to occur, the free hydroxyl group must first be converted into a 
leaving group, in this case an ester that is a dimer of compound 3-7. Evidence of precisely this 
β-elimination was first highlighted in Figure 2.2. The isolation of this product made it clear we 





Scheme 4.6 – Left-Hand Protecting Group Strategy 
Upon synthesis of compound 3.7, the protecting group strategy began with treating the 
carboxylic acid with NaHCO3 and allyl bromide to afford the allyl ester (Scheme 4.5). This allyl 
ester protecting group was chosen over that of a benzyl protection group used earlier in the 
synthesis, due to the deprotection conditions. The hydrogenation reaction most typically used to 
remove a benzyl group would also reduce the alkene necessary for the future ring closing 
metathesis, where deprotection of the alloc group with Pd(Ph3)4 should not touch the alkene. 
Following protection of the carboxylic acid, we protected the free hydroxyl group with TBDMS-
triflate, followed by subsequent deprotection of the alloc group. This afforded our appropriately 
protected left hand piece, compound 3.10, in a 71% yield. With the three major pieces of our 




4.6 Assembling the Macrocycle 
With the three major components of our macrocycle in hand, we had a choice to make. 
Should we build the macrocycle from left to right, or right to left? The decision was made to 
couple the central building block to the right-hand piece first, due challenges removing 
triphenylphosphine oxide (a byproduct of the Mitsunobu reaction) from the desired product. We 
felt that it was best to ensure this by-product was removed before assembly of the whole 
molecule. 
 
Scheme 4.7 – Assembly of the Macrocycle 
With this in mind, the previously synthesized central building block was treated with 
standard hydrogenation conditions to cleave the benzyl protecting group, affording a 90% yield 
of the acid that was carried forward without further purification. The isolated carboxylic acid 
then underwent the Mitsunobu reaction with the previously synthesized right-hand piece, 
affording compound 3-14 in an 88% yield, with no evidence of elimination product present. It 
appears without the presence of a strong base, the β-elimination does not occur as readily with 




Figure 4.5 – Challenges Faced with the N-Methyl Coupling 
This is the current stopping point for this approach to the synthesis due to significant 
challenges faced in coupling the N-Me amine (following Boc deprotection) to the left-hand 
portion of the molecule (Figure 4.5). Despite our efforts to devise a suitable protection strategy 
for the left-hand portion of our molecule, further evidence of the problematic β-elimination was 
isolated, with only trace evidence of coupled product observed in the proton NMR. Future 
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4.8 Experimental Procedures 
 
 
[Compound 3-1] To a flame dried round bottom flask was added 0.5041 g (1.67 mmol) L-
Threonine benzyl ester oxalate with 0.1485 g (1.75 mmol) NaHCO3. The flask was then brought 
to 0 °C and stirred in 5 mL THF with 5 mL H2O. To the stirring solution was added 0.16 mL 
(1.67 mmol) Acetic anhydride. The pH of the reaction was then adjusted to 10 using 1 M NaOH 
solution, and was allowed to stir and reach room temperature overnight. The reaction was then 
diluted with 30 mL H2O and extracted with EtOAc (3x35 mL). The combined organic layers 
were then dried with MgSO4 and concentrated in vacuo to afford 0.3118 g (74% yield) of 
compound 3-1 as a white solid. This product was carried forward without any further 
purification. 
1H NMR (300 MHz, Chloroform-d) δ 7.33 (d, J = 2.7 Hz, 5H), 6.67 (d, J = 8.9 Hz, 1H), 5.16 (s, 
2H), 4.60 (dd, J = 9.0, 2.5 Hz, 1H), 4.34 (dq, J = 6.4, 3.2 Hz, 1H), 2.03 (s, 3H), 1.17 (d, J = 6.4 
Hz, 3H);  δ 13C NMR (126 MHz, cdcl3) δ 170.97, 170.78, 135.22, 128.66, 128.66, 128.51, 
128.19, 128.19, 77.28, 77.03, 76.77, 68.06, 67.36, 57.35, 23.09, 20.02. Full characterization of 





[Compound 3-2] To a flame dried round bottom flask was added 0.499 g (1.67 mmol) L-
Threonine benzyl ester oxalate with 0.3506 g (4.17 mmol) NaHCO3. The flask was then brought 
to 0 °C and stirred in 6 mL THF with 6 mL H2O. To this stirring solution was added 0.65 mL 
(8.35 mmol) Methyl chloroformate dropwise. The reaction was allowed to stir and reach room 
temperature overnight. After 20 hours, the reaction was diluted with 50 mL EtOAc and washed 
with saturated NaHCO3 (3x30 mL). The combined aqueous layers were then back extracted with 
EtOAc (2x20 mL). All organic layers were then dried with MgSO4 and concentrated in vacuo to 
afford 0.3755 g (84% yield) of compound 3-2 as a clear oil. This product was carried forward 
without any further purification. 
1H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.25 (m, 5H), 5.99 (d, J = 9.3 Hz, 1H), 5.15 (s, 2H), 
4.37 – 4.28 (m, 2H), 3.64 (s, 3H), 1.20 (d, J = 6.5 Hz, 3H); 13C NMR (126 MHz, Chloroform-d) 
δ 13C NMR (126 MHz, cdcl3) δ 173.93, 160.30, 137.99, 131.24, 131.04, 130.98, 130.78, 130.78, 
80.17, 79.91, 79.65, 70.55, 69.92, 62.22, 55.19, 22.55. Full characterization of compound 3-2 
was not pursued as this synthetic route is still in development. 
 
 
[Compound 3-3] To a flame dried round bottom flask was added 1.0010 g (4.56 mmol) Boc-L-
threonine with 0.90522 g (22.6 mmol) NaH 60% dispersion in mineral oil. The flask was then 
brought to 0 °C before addition of 28 mL THF. To this stirring solution 2.8 mL Iodomethane was 
then carefully added. The reaction was allowed to stir and reach room temperature overnight. 
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After 24 hours, the flask was diluted with 50 mL DI H2O and concentrated in vacuo. The 
remaining aqueous layer was then brought to pH=3 with 1 M HCl, and was then extracted with 
EtOAc (3x35 mL). The crude product was then purified by flash chromatography (silica gel, 
70% Hexane: 30% EtOAC) to afford 0.7574 g (67% yield) of compound 3-3 as a clear oil. 
Trace impurity inseparable and was carried forward to the subsequent esterification.  
1H NMR (500 MHz, Chloroform-d) δ 7.03 – 6.83 (q, 1H), 4.95 – 4.61 (d, 1H), 4.02 (dq, J = 39.4, 
5.9 Hz, 1H), 3.36 – 3.29 (s, 3H), 3.01 – 2.94 (s, eH), 1.81 (d, J = 7.1, 2.4 Hz, 1H), 1.53 – 1.40 (s, 
9H), 1.18 (d, J = 10.2, 6.3 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 178.23, 159.80, 83.13, 79.12, 
66.04, 59.90, 37.99, 30.96, 30.94, 30.80, 17.85. Full characterization of compound 3-3 has been 
previously reported.1 
 
[Compound 3-4] A flame dried flask was brought to 0 °C with 0.2030 g (1.10 mmol) 
compound 3-1, 0.3789 g (1.98 mmol) EDC, and 0.0273 g (0.22 mmol) DMAP. To this flask was 
added 0.3264 g (1.32 mmol) of compound 3-3 in 16 mL DCM. The reaction was allowed to stir 
and reach room temperature overnight. After 48 hours, the reaction was diluted with 50 mL 
DCM. The organic layer was washed with saturated NaHCO3 (3x30 mL). The combined aqueous 
layers were then back extracted with DCM (2x20 mL). All organic layers were then dried with 
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography 




1H NMR (300 MHz, Chloroform-d) δ 7.32 – 7.24 (m, 5H), 5.39 (dq, J = 6.3, 2.8 Hz, 1H), 5.13 – 
5.00 (m, 3H), 4.87 (d, 1H), 3.85 (dq, J = 6.2 Hz, 1H), 3.20 (s, 3H), 2.82 (s, 3H), 2.01 (s, 3H), 
1.39 (s, 9H), 1.27 (d, 3H), 1.08 (d, J = 6.1 Hz, 3H). Full characterization of compound 3-4 was 
not obtained as this pathway was deemed unsuitable for future use. 
 
[Compound 3-5] A flame dried flask was brought to 0 °C with 0.6868 g (2.57 mmol) 
compound 3-2, 0.6940 g (3.63 mmol) EDC, and 0.0785 g (0.64 mmol) DMAP. To this flask was 
added 0.8972 g (3.63 mmol) of compound 3-3 in 16 mL DCM. The reaction was allowed to stir 
and reach room temperature overnight. After 48 hours, the reaction was diluted with 50 mL 
DCM. The organic layer was washed with saturated NaHCO3 (3x30 mL). The combined aqueous 
layers were then back extracted with DCM (2x20 mL). All organic layers were then dried with 
MgSO4 and concentrated in vacuo. The crude product was then purified by flash chromatography 
(silica gel, 80% Hexane: 20% EtOAC) to afford 0.9616 g (75% yield) of compound 3-5 as a 
clear oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.30 (m, 5H), 5.56 – 5.42 (m, 2H), 5.14 (s, 2H), 
4.86 (d, J = 5.0 Hz, 1H), 3.91 (dq, J = 17.7, 11.9, 6.1 Hz, 1H), 3.71 (s, 3H), 3.26 (s, 3H), 2.90 (s, 
3H), 1.46 (s, 9H), 1.36 (d, 3H), 1.14 (d, J = 6.6 Hz, 3H); 13C NMR (126 MHz, cdcl3) δ 172.19, 
171.78, 159.80, 159.44, 137.63, 131.28, 131.26, 131.15, 131.10, 131.06, 82.66, 73.87, 70.42, 
70.26, 64.72, 60.29, 59.62, 55.22, 35.44, 30.95, 30.95, 30.81, 19.59, 17.57. Full characterization 




[Compound 3-6] To a flame dried flask was added 0.5015 g (3.00 mmol) Phenylactic acid with 
1.4050 g (3.70 mmol) HATU which were then set to stir in 20 mL DMF. To this stirring solution 
was added 0.20 mL (2.50 mmol) N-allyl amine and 1.0 mL (6.00 mmol) DIPEA. The reaction 
was allowed to stir at room temperature overnight. After 20 hours, the reaction was diluted with 
50 mL EtOAc and washed with saturated NaHCO3 (3x30 mL). The combined aqueous layers 
were then back extracted with EtOAc (2x20 mL). All organic layers were then dried with MgSO4 
and concentrated in vacuo. The crude product was then purified by flash chromatography (silica 
gel, 60% Hexane: 40% EtOAC) to afford 0.4493 g (82% yield) of compound 3-6 as a clear oil. 
1H NMR (300 MHz, Chloroform-d) δ 7.34 – 7.18 (m, 5H), 6.79 (t, J = 6.1 Hz, 1H), 5.73 (m, 
1H), 5.14 – 5.04 (m, 2H), 4.26 (t, J = 8.5, 4.9, 3.8 Hz, 1H), 3.81 (m, J = 6.0, 4.6, 1.6 Hz, 2H), 
3.18 (dd, J = 13.9, 3.8 Hz, 1H), 2.84 (dd, J = 13.9, 8.3 Hz, 1H); 13C NMR (126 MHz, cdcl3) δ 
176.42, 140.26, 136.46, 132.32, 131.97, 130.86, 129.11, 118.76, 75.33, 43.91, 41.18. Full 
characterization of compound 3-6 was not pursued as this synthetic route is still in development. 
 
[Compound 3-7] A stirred solution of 0.37 mL (2.73 mmol) 6-Heptenoic acid and 0.33 mL 
(2.97 mmol) of 4-methylmorpholine in 8 mL THF was brought to -10 °C. To the stirring solution 
0.37 mL (2.86 mmol) isobutyl chloroformate was added and maintained at -10 °C for 30 
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minutes. The reaction was allowed to warm to 0 °C at which time 0.6423 g (3.51 mmol) of the 
hydrochloride salt of β-hydroxyluecine in 5.5 mL of 1 M NaOH was added. The reaction was 
allowed to warm to room temperature overnight and stirred for 24 hours. The reaction was then 
diluted with 30 mL H2O, and washed with EtOAc (2x25 mL). The combined organic layers were 
then extracted with saturated NaHCO3 (3x25 mL). All aqueous layers were combined and 
acidified to pH=2 with 1 M HCl and extracted with EtOAc (3x30 mL). The combined organic 
layers were then dried with MgSO4 and concentrated in vacuo to give 0.5695 g (81% yield) of 
compound 3-7 as a white foaming oil that was carried forward without further purification. 
1H NMR (500 MHz, Chloroform-d) δ 6.87 (d, J = 7.8 Hz, 1H), 5.84 – 5.75 (m, 1H), 5.04 – 4.94 
(m, 2H), 4.75 (d, J = 8.9, 1.9 Hz, 1H), 3.82 (dd, J = 9.3, 1.9 Hz, 1H), 2.33 (t, J = 27.5, 7.4 Hz, 
2H), 2.12 – 2.02 (m, 2H), 1.74 – 1.62 (m, 3H), 1.49 – 1.38 (m, 2H), 1.02 (d, J = 6.6 Hz, 3H), 
0.90 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, cdcl3) δ 181.27, 177.72, 140.99, 117.38, 57.18, 
38.74, 36.00, 33.45, 31.00, 27.76, 26.80, 21.85, 21.45. Full characterization of compound 3-7 
was not pursued as this synthetic route is still in development. 
 
[Compound 3-8] To a stirring solution of 0.3123 g (1.21 mmol) compound 3-7 with 0.4074 g 
NaHCO3 (4.85 mmol) in 5.8 mL DMF was added 0.89 mL (10.3 mmol) Allyl bromide in a 
dropwise fashion. The reaction was allowed to stir at room temperature overnight. After 20 hours 
the reaction was diluted with 30 mL H2O, and extracted with EtOAc (3x30 mL). The combined 
organic layers were then washed with saturated NaHCO3 (2x20 mL) then brine (1x20 mL). The 
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organic layer was then dried with MgSO4 and concentrated in vacuo. The crude product was then 
purified by flash chromatography (silica gel, 60% Hexane: 40% EtOAc) to give 0.2074 g (57% 
yield) of compound 3-8 as a clear oil. 
1H NMR (300 MHz, Chloroform-d) δ 6.48 (d, J = 9.2 Hz, 1H), 6.01 – 5.68 (m, 2H), 5.42 – 5.19 
(m, 2H), 5.10 – 4.85 (m, 2H), 4.83 (dt, J = 9.2, 2.0 Hz, 1H), 4.64 (dd, J = 5.8, 1.3 Hz, 2H), 3.74 
(dd, J = 9.0, 2.1 Hz, 1H), 2.27 (t, J = 7.5, 1.9 Hz, 2H), 2.14 – 1.99 (m, 2H), 1.67 (m, 3H), 1.51 – 
1.34 (m, 2H), 1.01 (d, J = 6.6, 1.9 Hz, 3H), 0.92 (d, J = 6.8, 2.0 Hz, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 13C NMR (126 MHz, cdcl3) δ 176.07, 174.18, 141.08, 134.23, 121.43, 117.31, 
80.09, 68.77, 56.77, 39.01, 36.06, 33.63, 31.04, 27.73, 21.55, 21.51. Full characterization of 
compound 3-8 was not pursued as this synthetic route is still in development. 
 
[Compound 3-9] To a stirring solution of 0.1362 g (0.45 mmol) compound 3-8 in 2.5 mL DCM 
at 0 °C was added 0.26 mL (2.29 mmol) 2,6-Lutidine, followed by dropwise addition of 0.26 mL 
(1.14 mmol) TBDMS-triflate. The reaction was allowed to stir and reach room temperature 
overnight. After 24 hours, the reaction was quenched with 1 M HCl (20 mL). Reaction was then 
extracted with DCM (3x25 mL). The combined organic layers were then washed with 1 M 
KHSO4(30 mL) and brine (30 mL). The organic layer was then dried with MgSO4 and 
concentrated in vacuo. The crude product was then purified by flash chromatography (silica gel, 
90% Hexane: 10% EtOAc) to give 0.1736 g (92% yield) of compound 3-9 as a clear oil. 
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1H NMR (500 MHz, Chloroform-d) δ 6.18 (d, J = 9.1 Hz, 1H), 5.92 (m, 1H), 5.85 – 5.76 (m, 
1H), 5.40 – 5.25 (m, 2H), 5.08 – 4.94 (m, 2H), 4.77 – 4.70 (d, 1H), 4.62 (dd, J = 4.5, 2.9, 1.4 Hz, 
2H), 4.00 (dd, J = 6.5, 3.3, 1.3 Hz, 1H), 2.33 – 2.25 (t, 2H), 2.14 – 2.06 (m, 2H), 1.86 – 1.76 (m, 
2H), 1.72 – 1.66 (m, 2H), 1.53 – 1.44 (m, 2H), 1.02 – 0.88 (m, 15H), 0.10 (s, 3H), 0.02 – -0.03 
(s, 3H). 13C NMR (126 MHz, cdcl3) δ 175.33, 173.93, 141.06, 134.22, 121.43, 117.32, 79.60, 
68.70, 56.15, 39.15, 36.07, 35.91, 30.99, 28.58, 28.31, 27.63, 21.77, 20.66, -0.93, -1.55, -2.13. 
Full characterization of compound 3-9 was not pursued as this synthetic route is still in 
development. 
 
[Compound 3-10] A stirred solution of 0.0463 g (0.04 mmol) Pd(PPh3)4 in 0.7 mL of THF was 
cooled to -78°C. To this was added 0.02 mL n-BuLi (0.04 mmol of a 2.5 molar solution in 
hexanes) and the solution was stirred at -78 for 1 hour at which time it was added to a separate 
stirred solution of 0.1696 g (0.41 mmol) compound 3-9 in 0.7 mL THF. Added immediately to 
this stirring solution was 0.35 mL (4.0 mmol) Morpholine. The reaction was stirred at room 
temperature for 2 hours at which time the reaction was diluted with 15 mL of diethyl ether and 
organic layer washed with 1 M KHSO4 (3x15 mL) and brine (15 mL). The organic layer was 
dried over MgSO4  and concentrated in vacuo. The crude product was then purified by flash 
chromatography (silica gel, 70% Hexane: 30% EtOAc) to give 0.072 g (71% yield) of 
compound 3-10 as a clear oil. 
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1H NMR (500 MHz, Chloroform-d) δ 6.27 (dd, J = 8.6, 2.5 Hz, 1H), 5.81 – 5.71 (m, 1H), 5.01 – 
4.88 (m, 2H), 4.62 (ddt, J = 8.6, 2.7, 1.3 Hz, 1H), 4.05 – 4.00 (m, 1H), 2.26 (td, J = 7.7, 2.9 Hz, 
2H), 2.03 (qdd, J = 7.0, 3.7, 1.4 Hz, 2H), 1.80 – 1.70 (m, 1H), 1.66 – 1.59 (m, 2H), 1.41 (dtd, J = 
15.1, 7.3, 3.9 Hz, 2H), 0.99 (ddd, J = 9.2, 4.8, 2.1 Hz, 1H), 0.92 (dt, J = 5.1, 2.6 Hz, 2H), 0.88 
(dt, J = 3.8, 2.0 Hz, 12H), 0.06 (dt, J = 2.8, 1.3 Hz, 3H), 0.00 (dd, J = 3.1, 1.1 Hz, 3H). 13C NMR 
(126 MHz, cdcl3) δ 179.42, 178.33, 142.92, 119.33, 81.23, 58.30, 41.00, 37.97, 37.72, 32.87, 
30.56, 30.24, 29.53, 23.60, 22.80, 22.74, 0.95, 0.24, 0.00. Full characterization of compound 3-
10 was not pursued as this synthetic route is still in development. 
 
 
[Compound 3-11] To a flame dried flak were added 0.2470 g (0.51 mmol) compound 3-4 and 
0.0180 g (0.17 mmol) Pd on Carbon in 2.3 mL MeOH. The flask was then placed under positive 
pressure of H2 and stirred vigorously and monitored by TLC until completion, between 6-8 
hours, at which time the reaction was diluted with 50 mL MeOH. The solution was then filtered 
through celite and concentrated in vacuo. The crude product, 0.1966 g (98%) compound 3-11, 
was carried forward without any further purification.  
 
[Compound 3-12] To a flame dried flak were added 0.4133 g (0.83 mmol) compound 3-5 and 
0.0306 g (0.27 mmol) Pd on Carbon in 4 mL MeOH. The flask was then placed under positive 
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pressure of H2 and stirred vigorously for The reaction was monitored by TLC until completion, 
between 6-8 hours, at which time the reaction was diluted with 50 mL MeOH. The solution was 
then filtered through celite and concentrated in vacuo. The crude product, 0.3280 g (97%) 
compound 3-12, was carried forward without any further purification. 
 
[Compound 3-13] In a flame dried round bottom flask 0.2007 g (0.51 mmol) compound 3-11 
was subjected to a benzene (30 mL) azeotropic distillation to remove any trace water. To this 
flask was added 0.1298 g (0.49 mmol) triphenylphosphine, followed by 1.8 mL THF. The flask 
was stirred at -30 °C before addition of 0.0965 g (0.47 mmol) compound 3-6 dissolved in an 
additional 1.8 mL THF, followed by dropwise addition of 0.24 mL (0.52 mmol) of a 40 wt % 
solution of Diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30 
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction 
was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with 
saturated NaHCO3 (3x25 mL). The Aqueous layer was then back extracted with EtOAc (2x20 
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The 
resulting oil was purified via flash column chromatography (silica gel, 100% Et2O) to afford 
0.2007 g (68% yield) of compound 3-13 as a clear foaming oil. 
1H NMR (300 MHz, Chloroform-d) δ 7.29 – 7.15 (m, 5H), 6.82 (d, J = 5.7 Hz, 1H), 5.82 – 5.62 
(m, 1H), 5.42 (dd, J = 9.1, 3.8 Hz, 1H), 5.10 – 5.00 (m, 2H), 4.69 (d, J = 5.7 Hz, 1H), 4.30 (dd, J 
= 7.4, 5.6 Hz, 1H), 3.96 – 3.79 (m, 2H), 3.24 (s, J = 2.3 Hz, 3H), 3.20 – 3.14 (m, 1H), 3.12 – 
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3.02 (m, 1H), 2.87 (s, J = 11.4 Hz, 3H), 1.95 (s, J = 6.3 Hz, 3H), 1.50 – 1.38 (s, 9H), 1.17 – 1.11 
(d, 3H), 0.81 (d, J = 6.4 Hz, 3H). Full characterization of compound 3-13 was not obtained as 
this pathway was deemed unsuitable for future use. 
 
[Compound 3-14] In a flame dried round bottom flask 0.3186 g (0.78 mmol) compound 3-12 
was subjected to a benzene (30 mL) azeotropic distillation to remove any trace water. To this 
flask was added 0.1975 g (0.75 mmol) triphenylphosphine, followed by 2.8 mL THF. The flask 
was stirred at -30 °C before addition of 0.1900 g (0.93 mmol) compound 3-6 dissolved in an 
additional 2.8 mL THF, followed by dropwise addition of 0.37 mL (0.82 mmol) of a 40 wt % 
solution of Diethyl azodicarboxylate in toluene. The temperature was maintained at -30 °C for 30 
minutes and was then allowed to reach room temperature overnight. After 18 hours, the reaction 
was concentrated in vacuo. The resulting oil was dissolved in 50 mL EtOAc and washed with 
saturated NaHCO3 (3x25 mL). The Aqueous layer was then back extracted with EtOAc (2x20 
mL). The combined organic layers were then dried with MgSO4 and concentrated in vacuo. The 
resulting oil was purified via flash column chromatography (silica gel, 50% Hexane: 10% 
EtOAc: 40% Et2O) to afford 0.4097 g (88% yield) of compound 3-14 as a clear foaming oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.29 – 7.20 (m, 6H), 6.87 (t, J = 5.9 Hz, 1H), 5.78 – 5.69 
(m, 1H), 5.45 (dd, J = 8.2, 4.3 Hz, 1H), 5.18 (dd, J = 13.4, 6.7 Hz, 1H), 5.05 (dq, J = 14.0, 1.8 
Hz, 2H), 4.77 (d, J = 5.4 Hz, 1H), 4.27 (t, J = 6.5 Hz, 1H), 3.92 (p, J = 6.2 Hz, 1H), 3.88 – 3.80 
(m, 1H), 3.65 (s, 3H), 3.38 – 3.31 (m, 1H), 3.25 (s, 2H), 3.12 (dt, J = 14.3, 7.1 Hz, 1H), 2.91 (s, 
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2H), 1.44 (d, J = 17.3 Hz, 9H), 1.15 (t, J = 7.1 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H); 13C NMR (126 
MHz, cdcl3) δ 172.64, 172.06, 170.91, 159.87, 159.50, 138.70, 136.37, 132.35, 132.13, 131.09, 
130.82, 118.76, 82.93, 79.08, 78.43, 72.83, 65.17, 61.47, 59.46, 55.27, 44.35, 40.30, 35.70, 
30.92, 30.77, 30.76, 23.66, 19.50, 17.60. Full characterization of compound 3-14 was not 








Figure 5.1 – β-Elimination of the Bottom Bridge Analog 
The effort to improve efficacy and potency of our simplified analogs is continuing with 
the development of a convergent synthesis of analogs that contain an intact central building 
block, or “bottom bridge” of the macrocycle. In this case, another pair of β-elimination reactions 
continue to interfere with our progress. These β-elimination reactions involve the protons 
highlighted in red in Figure 5.1. One destabilizes the functionalized bottom bridge, and the other 
complicates the coupling of the N-methylamine within our central building block to the 
carboxylic acid of left-hand portion of the macrocycle. While the exchange of the acetyl 
protecting group to a methyl carbamate within the central building block improved yields and 
slowed the β-elimination reaction, it is still problematic. The challenges with the formation of the 
N-methyl amide have yet to be completely resolved, although progress is currently being made 
by Dr. Yu Zhu in our group. The current hypothesis as to the challenges with the coupling 
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reaction are highlighted in Figure 5.2. We propose that the challenge is related to problems 
associated with coupling a NAcyl amino acid that were previously highlighted in Figure 2.5. 
 
Figure 5.2 – Plausible Oxazolone Formation 
To be more specific, it is possible, regardless of the size of the R group, that the 
intramolecular nucleophilic trapping by the acyl amine of the activated ester necessary for the 
desired coupling is faster than the bimolecular coupling. Following the displacement of the 
leaving group for the activated ester, deprotonation of the proton involved in the β-elimination 
results in an aromatic intermediate that rapidly undergoes the elimination of the TBS-alcohol. 
While the ring opening of the oxazolone may be reversible, the β-elimination reaction is not. It 
possible the opening of the oxazolone ring could lead to coupled product or be lost upon aqueous 
work up. Efforts to solve this problem will be discussed in Section 5.2, though our experience 
from the first-generation synthesis of WU-07047 suggests that at the very least the the β-
elimination at the core of the bottom bridge will continue to complicate the synthesis until the 
macrocycle is assembled. 
Despite this decomposition pathway, we chose to push forward in an attempt to 
determine if the efficacy and potency would be improved through the installation of the bottom 
bridge. We knew moving forward that this particular reaction sequence would not be scalable in 
the future, but we hoped that positive result on the biological front would provide a foundation 
for the synthetic efforts necessary to overcome the problems we have encountered. However, 
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while trace amounts of material have been isolated from the coupling to the left-hand portion, the 
amount of material generated have not been in sufficient yield to determine if the ring closing 
metathesis strategy will be successful moving forward. The decision was made to carry trace 
amounts of crude product forward to the ring closing metathesis (in order to reduce the risk of β-
elimination) but these efforts were inconclusive. Following purification after the metathesis 
reaction, it was evident that polymeric product had been generated.  We hypothesize that the 
refluxing conditions necessary for the ring closing metathesis may increase the rate of the 
problematic β-elimination. However, we need to be cautious drawing conclusions regarding the 
metathesis reaction since the substrate for the reaction has not been characterized with respect to 
purity. 
The combined problems encountered with this route suggest that we should be devising 
alternative strategies for the synthesis of more the functionalized analogs. What follows is a brief 
discussion of future more functionalized analogs, and possible options aimed at avoiding the 
issues discussed above. 
5.2 Future Directions 
Looking forward, if we intend to use the convergent approach outlined in Figure 4.1 to 
synthesize more complex analogs, we must first address the challenges of coupling the central 
building block to the left-hand piece. There is literature evidence of the success of a 
macrolactamization of the NMe-amine of threonine (of our central building block) to the β-
hydroxyleucine (of our left-hand piece), although no yield is reported for this reaction.1 With the 
knowledge that this coupling can be successful, there are two possible protecting group strategies 
that may remedy the issue that we have observed to date. It may be plausible to find a suitable 
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protecting group for the hydroxyl group in our left-hand portion that will avoid the β-elimination, 
although we chose the TBDMS ether in an effort to do just that (Figure 5.3). If this approach 
continues to be unsuccessful, we could alter the protecting group on the neighboring amine of the 
left-hand piece to that of a carbamate group. We have already observed that a change from an 
acyl group to a carbamate protecting group on an amine of an amino acid can reduce or eliminate 
oxazolone formation in subsequent coupling reactions. There is evidence from Dr. Yu Zhu in our 
group that such an approach can be successful. However, here we will emphasize the protecting 
group strategy involving the hydroxy group of the left-hand piece. Solving the problem in this 
manner will result in a shorter synthesis overall, eliminating the need to juggle protection groups 
in the steps after the desired coupling reaction. Remember that the length of the synthesis may be 
incredibly important because of the potential loss of material due to the β-elimination within the 
bottom bridge during each subsequent reaction (Figure 4.2). 
 
Figure 5.3 – Protection Strategies that Reduce the β-Elimination 
There are two possible approaches when choosing a protecting group for the left-hand 
piece. We can either find a protecting group that would result in the oxygen being an unstable 
leaving group, or a protecting group large enough to prevent any base from accessing the proton 
(highlighted red) responsible for the β-elimination. A few such options to consider would be a 
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TIPS, trityl, or benzyl protecting group. In each case, the hope is that the protecting group would 
be more stable than the TBS group. This is based upon the evidence of the β-elimination in both 
the TBS protected left-hand piece, the left-hand piece with the unprotected hydroxyl group 
(Figure 4.4-5) and the plausible oxazolone formation mechanism highlighted in Figure 5.2. 
 
Figure 5.4 – Ring Closing Macrolactamization 
This protecting group strategy will be necessary for any analog synthesized based on the 
current convergent approach (Figure 5.4). Once the problem of the coupling reaction has been 
resolved (there is precedence that indicates it is a solvable problem), we will need to turn our 
attention to formation of the macrocycle. For this transformation, it may be necessary to avoid 
the elevated temperatures typically associated with the ring closing metathesis reaction. These 
harsher conditions may trigger the unwanted β-elimination reactions. One approach that would 
avoid these harsh conditions would use a ring closing macrolactamization (highlighted red) to 
complete the synthesis of macrocycle. Once the macrocycle has been generated, the β-
elimination within the bottom bridge should no longer be possible. We can then add the β-
hydroxy leucine tail in a similar manner as the second-generation synthesis. 
If the methods that discussed above that attempt to reduce the β-elimination are not 





Figure 5.5 – Analogs that Avoid the β-Elimination 
There are several approaches we have considered to avoid the β-elimination within our 
central building block, two of which are actively being pursued in our lab. In the first analog 
shown above (left, Figure 4.5), the carbonyl of the threonine of our central building block has 
been reduced (highlighted red). This change would make the molecule more stable by 
significantly reducing the leaving group ability of the portion of the molecule eliminated in the 
unwanted side-reaction.  
 
Scheme 5.1 – Threonine Reduction 
The synthesis of this analog can in principle be accomplished by reduction of the 
carboxylic acid in the original demethylated amino acid, conversion of the resulting hydroxy 
group to a leaving group, and an SN2 type displacement of the leaving group by the secondary 
alcohol of the threonine (Scheme 5.1).  
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It is also possible to prevent the problematic β-elimination entirely through removal of 
the problematic acidic proton via methylation (highlighted red) of the α-carbon of the right-hand 
threonine (right, Figure 5.5). Amino acids of this nature have been synthesized.2 While these 
options are plausible synthetically, the strategies may not be tolerated from the standpoint of 
biological activity. 
In addition, one could consider the use of a ring closing macrolactonization (highlighted 
red) to complete the synthesis of our macrocycle (right, Figure 5.5).  While this will require an 
alternative coupling approach to assemble the acyclic molecule, by ring closing at the threonine 
dimer, we would entirely avoid the chance of the β-elimination prior to forming the macrocycle 
while still retaining the bottom bridge found in the natural products. 
 
Figure 5.6 – Top Bridge Carbamate Analog 
One final approach to consider is the use of a carbamate within the top bridge (Figure 
5.6). The use of a carbamate in place of the amide found in the natural product should help avoid 
oxazolone formation under standard coupling conditions. The installation of this the top bridge 
with a carbamate will allow us to use the same building block approach to piece together the 
linear molecule prior to the use of a ring closing metathesis to tie together the macrocycle. If this 
method is unsuccessful, one could envision assembling the linear molecule in a stepwise fashion 




Scheme 5.2: Carbamate Coupling Strategy 
 Efforts are currently underway in our lab if assembly of this molecule in a linear fashion 
will avoid carbamate formation. Evidence found by Dr. Yu Zhu in our lab indicates that the 
coupling between the NMe-OMe-Thr of the central building block, to the Boc protected β-
hydroxy leucine of the left hand piece is possible. 
 
Figure 5.7 – Bioorthogonal Handle Analog 
As we work to improve the potency and efficacy of our simplified analogs, it is becoming 
clear we need to devise a rapid way to screen molecules for activity prior to the use of expensive 
and time-consuming whole cell assays that are currently used. To this end, we are interested 
installing a biorthogonal handle (R) such as an alkyne or an aryl bromide (Figure 5.7). This will 
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serve two purposes, first, both groups have been used to place molecules onto microelectrode 
arrays to monitor for binding to biological targets.3 Second, this synthetic addition will also 
provide our medical school collaborators a handle for labeling the analogs in connection with 
future biological assays. Both handles can be used to add several probes to previously 
synthesized analogs. In Figure 5.7, I have suggested a site (highlighted red) where this handle 
could potentially be installed. This site was chosen because the inclusion of larger groups at this 
position in the natural product have been tolerated.4 For example, as discussed in Section 1.3, the 
substitution of a phenyl group for the methyl group found in the natural product has been 
tolerated with no significant loss in activity. The installation of an amino acid with a 
bioorthoganal handle can be accomplished through standard coupling reactions. 
All this work is currently underway in the Moeller group. These efforts seek to improve 
potency and efficacy towards that found in the natural products, the development of methods for 
the rapid screening of newly synthesized analogs, and the scaling of the synthesis for building 
YM- and FR-analogs. These analogs will prove invaluable for probing the G protein signaling 
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Appendix: Spectral Data 
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